266485

ACCESS DB #

FOR OFFICIAL USE ONLY RECEIVED PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQ

Requester's Full Name: Kristin Bianchi Date: 7/16/08
Art Unit: 1626 Phone Number: 305232 Serial Number: 10/537630
Location (Bldg/Room#): Remsen (Mailbox #): 5A18 Results Format Preferred (circle): PAPER (DISK)
email or SCORE (please no floppy disks)

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Indole Acetic Acid Derivatives & Their Use as Pharmaceutical Agents, Intermediates and Process of Preparation

Inventors (please provide full names): Louis-David Cantin, Sangyun Choi, Roger Clark, Martin Hentemann, Xin Ma, Joachim Rudolph, Sidney Liang, Christiana Akuche, Rico Lavoie, Liping Chen, Dyatlova Philip Wickens

Earliest Priority Date: 12/20/02

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

please search claim 1 wherein L is
$-Y-(CH_2)_n-X-$ & Ar is phenyl
optionally substituted @ any available
position by 1 to 5 independently
selected R^8 groups (see attached sheet after
claim 1). Can leave R^6 & R^7 undefined
to simplify search. Also, can leave
optional substituents of mono or bicyclic
ring radical undefined.

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 17:17:27 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 20 Jul 2008 (20080720/ED)

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L63
L30 42 SEA FILE=ZCAPLUS ABB=ON PLU=ON CANTIN L?/AU
L31 14960 SEA FILE=ZCAPLUS ABB=ON PLU=ON CHOI S?/AU
L32 2383 SEA FILE=ZCAPLUS ABB=ON PLU=ON CLARK C?/AU
L33 24 SEA FILE=ZCAPLUS ABB=ON PLU=ON HENTEMANN M?/AU
L34 9485 SEA FILE=ZCAPLUS ABB=ON PLU=ON MA X?/AU
L35 494 SEA FILE=ZCAPLUS ABB=ON PLU=ON RUDOLPH J?/AU
L36 3094 SEA FILE=ZCAPLUS ABB=ON PLU=ON LIANG S?/AU
L37 9 SEA FILE=ZCAPLUS ABB=ON PLU=ON AKUCHE C?/AU
L38 45 SEA FILE=ZCAPLUS ABB=ON PLU=ON LAVOIE R?/AU
L39 27523 SEA FILE=ZCAPLUS ABB=ON PLU=ON CHEN L?/AU
L40 553 SEA FILE=ZCAPLUS ABB=ON PLU=ON MAJUMDAR D?/AU
L41 31 SEA FILE=ZCAPLUS ABB=ON PLU=ON WICKENS P?/AU
L42 12 SEA FILE=ZCAPLUS ABB=ON PLU=ON L30 AND (L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L43 44 SEA FILE=ZCAPLUS ABB=ON PLU=ON L31 AND (L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L44 1 SEA FILE=ZCAPLUS ABB=ON PLU=ON L32 AND (L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L45 6 SEA FILE=ZCAPLUS ABB=ON PLU=ON L33 AND (L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L46 137 SEA FILE=ZCAPLUS ABB=ON PLU=ON L34 AND (L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L47 10 SEA FILE=ZCAPLUS ABB=ON PLU=ON L35 AND (L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L48 32 SEA FILE=ZCAPLUS ABB=ON PLU=ON L36 AND (L37 OR L38 OR L39 OR L40 OR L41)
L49 2 SEA FILE=ZCAPLUS ABB=ON PLU=ON L37 AND (L38 OR L39 OR L40 OR L41)
L50 3 SEA FILE=ZCAPLUS ABB=ON PLU=ON L38 AND (L39 OR L40 OR L41)
L51 9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L39 AND (L40 OR L41)
L52 4 SEA FILE=ZCAPLUS ABB=ON PLU=ON L40 AND L41
L53 12 SEA FILE=ZCAPLUS ABB=ON PLU=ON L42 AND (L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52)
L54 5 SEA FILE=ZCAPLUS ABB=ON PLU=ON L43 AND (L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52)
L55 0 SEA FILE=ZCAPLUS ABB=ON PLU=ON L44 AND (L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52)

```
L56           5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L45 AND (L46 OR L47 OR L48 OR
                L49 OR L50 OR L51 OR L52)
L57           7 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L46 AND (L47 OR L48 OR L49 OR
                L50 OR L51 OR L52)
L58           9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L47 AND (L48 OR L49 OR L50 OR
                L51 OR L52)
L59           5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L48 AND (L49 OR L50 OR L51 OR
                L52)
L60           1 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L49 AND (L50 OR L51 OR L52)
L61           2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L50 AND (L51 OR L52)
L62           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L51 AND L52
L63          18 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L53 OR L54 OR L55 OR L56 OR
                L57 OR L58 OR L59 OR L60 OR L61 OR L62)


=> file medline embase biosis
FILE 'MEDLINE' ENTERED AT 17:17:44 ON 21 JUL 2008

FILE 'EMBASE' ENTERED AT 17:17:44 ON 21 JUL 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:17:44 ON 21 JUL 2008
Copyright (c) 2008 The Thomson Corporation

=> d stat que L64
L30          42 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CANTIN L?/AU
L31       14960 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CHOI S?/AU
L32        2383 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CLARK C?/AU
L33          24 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  HENTEMANN M?/AU
L34        9485 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MA X?/AU
L35         494 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  RUDOLPH J?/AU
L36        3094 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LIANG S?/AU
L37           9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  AKUCHE C?/AU
L38          45 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LAVOIE R?/AU
L39       27523 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CHEN L?/AU
L40         553 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MAJUMDAR D?/AU
L41          31 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  WICKENS P?/AU
L42          12 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L30 AND (L31 OR L32 OR L33 OR
                L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L43          44 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L31 AND (L32 OR L33 OR L34 OR
                L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L44           1 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND (L33 OR L34 OR L35 OR
                L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L45           6 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L33 AND (L34 OR L35 OR L36 OR
                L37 OR L38 OR L39 OR L40 OR L41)
L46         137 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L34 AND (L35 OR L36 OR L37 OR
                L38 OR L39 OR L40 OR L41)
L47          10 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L35 AND (L36 OR L37 OR L38 OR
                L39 OR L40 OR L41)
L48          32 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L36 AND (L37 OR L38 OR L39 OR
                L40 OR L41)
L49           2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L37 AND (L38 OR L39 OR L40 OR
                L41)
L50           3 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L38 AND (L39 OR L40 OR L41)
L51           9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L39 AND (L40 OR L41)
L52           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L40 AND L41
L53          12 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND (L43 OR L44 OR L45 OR
                L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52)
L54           5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L43 AND (L44 OR L45 OR L46 OR
                L47 OR L48 OR L49 OR L50 OR L51 OR L52)
```

```
L55           0 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L44 AND (L45 OR L46 OR L47 OR
                L48 OR L49 OR L50 OR L51 OR L52)
L56           5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L45 AND (L46 OR L47 OR L48 OR
                L49 OR L50 OR L51 OR L52)
L57           7 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L46 AND (L47 OR L48 OR L49 OR
                L50 OR L51 OR L52)
L58           9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L47 AND (L48 OR L49 OR L50 OR
                L51 OR L52)
L59           5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L48 AND (L49 OR L50 OR L51 OR
                L52)
L60           1 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L49 AND (L50 OR L51 OR L52)
L61           2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L50 AND (L51 OR L52)
L62           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L51 AND L52
L63          18 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L53 OR L54 OR L55 OR L56 OR
                L57 OR L58 OR L59 OR L60 OR L61 OR L62)
L64          19 SEA L63



=> file wpix
FILE 'WPIX' ENTERED AT 17:18:07 ON 21 JUL 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED:                          15 JUL 2008   <20080715/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE:     200845      <200845/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of
    March 2008. No update date (UP) has been created for the
    reclassified documents, but they can be identified by
    20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC,
    20071130/UPIC and 20080401/UPIC.
    ECLA reclassifications to April and US national classifications to
    the end of January 2008 have also been loaded. Update dates
    20080401/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Please note that the COPYRIGHT notification has changed <<<

'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d stat que L65
L30          42 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CANTIN L?/AU
L31       14960 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CHOI S?/AU
L32        2383 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CLARK C?/AU
L33          24 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  HENTEMANN M?/AU
L34        9485 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MA X?/AU
L35         494 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  RUDOLPH J?/AU
```

```
L36         3094 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LIANG S?/AU
L37            9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  AKUCHE C?/AU
L38           45 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LAVOIE R?/AU
L39        27523 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  CHEN L?/AU
L40          553 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  MAJUMDAR D?/AU
L41           31 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  WICKENS P?/AU
L42           12 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L30 AND (L31 OR L32 OR L33 OR
                 L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L43           44 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L31 AND (L32 OR L33 OR L34 OR
                 L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L44            1 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L32 AND (L33 OR L34 OR L35 OR
                 L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L45            6 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L33 AND (L34 OR L35 OR L36 OR
                 L37 OR L38 OR L39 OR L40 OR L41)
L46          137 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L34 AND (L35 OR L36 OR L37 OR
                 L38 OR L39 OR L40 OR L41)
L47           10 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L35 AND (L36 OR L37 OR L38 OR
                 L39 OR L40 OR L41)
L48           32 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L36 AND (L37 OR L38 OR L39 OR
                 L40 OR L41)
L49            2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L37 AND (L38 OR L39 OR L40 OR
                 L41)
L50            3 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L38 AND (L39 OR L40 OR L41)
L51            9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L39 AND (L40 OR L41)
L52            4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L40 AND L41
L53           12 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L42 AND (L43 OR L44 OR L45 OR
                 L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52)
L54            5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L43 AND (L44 OR L45 OR L46 OR
                 L47 OR L48 OR L49 OR L50 OR L51 OR L52)
L55            0 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L44 AND (L45 OR L46 OR L47 OR
                 L48 OR L49 OR L50 OR L51 OR L52)
L56            5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L45 AND (L46 OR L47 OR L48 OR
                 L49 OR L50 OR L51 OR L52)
L57            7 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L46 AND (L47 OR L48 OR L49 OR
                 L50 OR L51 OR L52)
L58            9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L47 AND (L48 OR L49 OR L50 OR
                 L51 OR L52)
L59            5 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L48 AND (L49 OR L50 OR L51 OR
                 L52)
L60            1 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L49 AND (L50 OR L51 OR L52)
L61            2 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L50 AND (L51 OR L52)
L62            4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L51 AND L52
L65            9 SEA FILE=WPIX ABB=ON  PLU=ON  (L53 OR L54 OR L55 OR L56 OR L57
                 OR L58 OR L59 OR L60 OR L61 OR L62)



=> dup rem L63 L64 L65
FILE 'ZCAPLUS' ENTERED AT 17:18:25 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:18:25 ON 21 JUL 2008

FILE 'EMBASE' ENTERED AT 17:18:25 ON 21 JUL 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:18:25 ON 21 JUL 2008
```

FILE 'WPIX' ENTERED AT 17:18:25 ON 21 JUL 2008
COPYRIGHT (C) 2008 THOMSON REUTERS
PROCESSING COMPLETED FOR L63
PROCESSING COMPLETED FOR L64
PROCESSING COMPLETED FOR L65
L66 19 DUP REM L63 L64 L65 (27 DUPLICATES REMOVED)
ANSWERS '1-18' FROM FILE ZCAPLUS
ANSWER '19' FROM FILE BIOSIS

=> d ibib abs L66 1-18; d iall L66 19

L66 ANSWER 1 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2007:1059556 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:397858
TITLE: Quinazolinone Derivatives as Orally Available Ghrelin Receptor Antagonists for the Treatment of Diabetes and Obesity
AUTHOR(S): Rudolph, Joachim; Esler, William P.; O'Connor, Stephen; Coish, Philip D. G.; Wickens, Philip L.; Brands, Michael; Bierer, Donald E.; Bloomquist, Brian T.; Bondar, Georgiy; Chen, Libing; Chuang, Chih-Yuan; Claus, Thomas H.; Fathi, Zahra; Fu, Wenlang; Khire, Uday R.; Kristie, James A.; Liu, Xiao-Gao; Lowe, Derek B.; McClure, Andrea C.; Michels, Martin; Ortiz, Astrid A.; Ramsden, Philip D.; Schoenleber, Robert W.; Shelekhin, Tatiana E.; Vakalopoulos, Alexandros; Tang, Weifeng; Wang, Lei; Yi, Lin; Gardell, Stephen J.; Livingston, James N.; Sweet, Laurel J.; Bullock, William H.
CORPORATE SOURCE: Departments of Chemistry Research, Metabolic Disorders Research, and Research Technologies, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(21), 5202-5216
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:397858
AB The peptide hormone ghrelin is the endogenous ligand for the type 1a growth hormone secretagogue receptor (GHS-R1a) and the only currently known circulating appetite stimulant. GHS-R1a antagonism has therefore been proposed as a potential approach for obesity treatment. More recently, ghrelin has been recognized to also play a role in controlling glucose-induced insulin secretion, which suggests another possible benefit for a GHS-R1a antagonist, namely, the role as an insulin secretagogue with potential value for diabetes treatment. In our labs., piperidine-substituted quinazolinone derivs. were identified as a new class of small-mol. GHS-R1a antagonists. Starting from an agonist with poor oral bioavailability, optimization led to potent, selective, and orally bioavailable antagonists. In vivo efficacy evaluation of selected compds. revealed suppression of food intake and body weight reduction as well as glucose-lowering effects mediated by glucose-dependent insulin secretion.
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 2 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2007:746530 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:343978
TITLE: Indanylacetic acids as PPAR-δ activator insulin sensitizers
AUTHOR(S): Wickens, Philip; Zhang, Chengzhi; Ma, Xin; Zhao, Qian; Amatruda, John; Bullock, William; Burns, Michael; Cantin, Louis-David; Chuang, Chih-Yuan; Claus, Thomas; Dai, Miao; Dela Cruz, Fernando; Dickson, David; Ehrgott, Frederick J.; Fan, Dongping; Heald, Sarah; Hentemann, Martin; Iwuagwu, Christiana I.; Johnson, Jeffrey S.; Kumarasinghe, Ellalahewage; Ladner, David; Lavoie, Rico; Liang, Sidney; Livingston, James N.; Lowe, Derek; Magnuson, Steve; Mannelly, Gretchen; Mugge, Ingo; Ogutu, Herbert; Pleasic-Williams, Susan; Schoenleber, Robert W.; Shapiro, Jeff; Shelekhin, Tatiana; Sweet, Laurel; Town, Christopher; Tsutsumi, Manami
CORPORATE SOURCE: Department of Chemistry Research, Bayer Research Center, West Haven, CT, 06516, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4369-4373
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:343978
GI



I

AB A series of indanylacetic acid derivs. I (X = O, S; R = H, 4-OMe, 3-OMe, 4-iPr, 3-F, 4-F, 4-Ph, 4-Me, 3-Me, 4-Cl, etc.) were prepared and they show a spectrum of activity as insulin sensitizers and PPAR-α and PPAR-δ ligands. In vivo data are presented for the title compds. as insulin sensitizers with selectivity for PPAR-δ over PPAR-α.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 3 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2007:478008 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:95523
TITLE: PDE-10A inhibitors as insulin secretagogues
AUTHOR(S): Cantin, Louis-David; Magnuson, Steven; Gunn, David; Barucci, Nicole; Breuhaus, Marina; Bullock, William H.; Burke, Jennifer; Claus, Thomas H.; Daly, Michelle; DeCarr, Lynn; Gore-Willse, Ann; Hoover-Litty, Helana; Kumarasinghe, Ellalahewage S.; Li, Yaxin; Liang, Sidney X.; Livingston, James N.; Lowinger, Timothy; MacDougall, Margit; Ogutu, Herbert O.; Olague, Alan; Ott-Morgan, Ronda; Schoenleber, Robert W.; Tersteegen, Adrian; Wickens, Philip; Zhang, Zhonghua; Zhu, Jian;

Zhu, Lei; Sweet, Laurel J.
CORPORATE SOURCE: Department of Chemistry Research, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2869-2873
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:95523
GI



I

AB Modulation of cAMP levels has been linked to insulin secretion in preclin. animal models and in humans. The high expression of PDE-10A in pancreatic islets suggested that inhibition of this enzyme may provide the necessary modulation to elicit increased insulin secretion. Using an HTS approach, quinoline-based PDE-10A inhibitors I [R1 = H, 6-F, 6-Cl, 6-MeO, 8-Me, 5,6-F2, etc.; R2 = 2-F, 3-F, 2-Me, 3-Me; R3 = H, Me, Et, Ph; X = CH2, (CH2)3, (R)-CHMe, etc.] were identified as insulin secretagogues in vitro. Optimized compds. were evaluated in vivo where improvements in glucose tolerance and increases in insulin secretion were measured.
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 4 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2007:477976 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:95594
TITLE: Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity
AUTHOR(S): Smith, Roger A.; Fathi, Zahra; Achebe, Furahi; Akuche, Christiana; Brown, Su-Ellen; Choi, Soongyu; Fan, Jianmei; Jenkins, Susan; Kluender, Harold C. E.; Konkar, Anish; Lavoie, Rico; Mays, Ronald; Natoli, Jennifer; O'Connor, Stephen J.; Ortiz, Astrid A.; Su, Ning; Taing, Christy; Tomlinson, Susan; Tritto, Theresa; Wang, Gan; Wirtz, Stephan-Nicholas; Wong, Wai; Yang, Xiao-Fan; Ying, Shihong; Zhang, Zhonghua
CORPORATE SOURCE: Department of Chemistry Research, Pharmaceuticals Division, Bayer HealthCare, West Haven, CT, 06516, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2706-2711

CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:95594

AB Several imidazole-based cyclohexyl amides were identified as potent CB-1 antagonists, but they exhibited poor oral exposure in rodents. Incorporation of a hydroxyl moiety on the cyclohexyl ring provided a dramatic improvement in oral exposure, together with a .apprx.10-fold decrease in potency. Further optimization provided N-((1S,2S)-2- hydroxycyclohexyl)-1-(4-bromophenyl)-2-(2-chlorophenyl)-5-ethyl-1H- imidazole-4-carboxamide, which exhibited hCB-1 Ki = 3.7 nM, and caused significant appetite suppression and robust, dose-dependent reduction of body weight gain in industry-standard rat models.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 5 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2007:129797 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:379922
TITLE: Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups - new classes of PPAR γ/δ and PPAR α/γ/δ agonists
AUTHOR(S): Cantin, Louis-David; Liang, Sidney; Ogutu, Herbert; Iwuagwu, Christiana I.; Boakye, Ken; Bullock, William H.; Burns, Michael; Clark, Roger; Claus, Thomas; dela Cruz, Fernando E.; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Keiper, Christine; Livingston, James N.; Schoenleber, Robert W.; Shapiro, Jeffrey; Town, Christopher; Yang, Ling; Tsutsumi, Manami; Ma, Xin
CORPORATE SOURCE: Department of Chemistry Research, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(4), 1056-1061
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:379922
GI



I

AB Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications. The

indanylacetic acid structural motif has proven useful in the generation of potent and tunable PPAR ligands. Modification of the substituents on the linker and the heterocycle tail group allowed for the modulation of the selectivity at the different receptor subtypes. Compound I was evaluated in vivo, where it displayed the desired reduction of glucose levels and increase in HDL levels in various animal models.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 6 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2007:126146 ZCAPLUS Full-text

DOCUMENT NUMBER: 146:379894

TITLE: Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α/γ/δ pan agonists: synthesis, structure-activity relationship, and in vivo efficacy

AUTHOR(S): Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Dela Cruz, Fernando E.; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; Schoenleber, Robert W.; Shapiro, Jeffrey; Yang, Ling; Tsutsumi, Manami; Ma, Xin

CORPORATE SOURCE: Bayer HealthCare Pharmaceuticals Corporation, West Haven, CT, 06516, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(5), 984-1000 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:379894

GI



I

AB Compds. that simultaneously activate the three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, gamma, and delta hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic syndrome. It was recently identified the indanylacetic acid moiety as a well-tunable PPAR agonist head group. Herein, the synthesis and structure-activity relationship (SAR) studies of aryl tail group derivs. that led to a class of potent PPAR pan agonists was reported. While most of the tail group modifications imparted potent PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required the introduction of new heterocyclic substituents that were not known in the PPAR literature. Systematic optimization led to the discovery of 4-thiazolyl-Ph derivs. with potent PPAR alpha/gamma/delta pan agonistic activity. From this series, the lead candidate I was found to exhibit excellent ADME properties and superior therapeutic potential compared to known PPAR gamma activating agents by favorably modulating lipid levels in hApoA1 mice and hyperlipidemic hamsters, while normalizing glucose levels in diabetic rodent models.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 7 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2006:104528 ZCAPLUS Full-text
DOCUMENT NUMBER: 144:192275
TITLE: Preparation of quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
INVENTOR(S): Rudolph, Joachim; O'Connor, Stephen; Coish, Philip; Wickens, Philip; Bondar, Georgiy; Chuang, Chih-Yuan; Ramsden, Philip; Lowe, Derek; Bierer, Donald; Chen, Libing; Fu, Wenlang; Khire, Uday; Liu, Xiao-Gao; Mcclure, Andrea; Wang, Lei; Yi, Lin; Esler, William
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 559 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012577	A2	20060202	WO 2005-US26192	20050722
WO 2006012577	A3	20060928		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-590804P P 20040722
OTHER SOURCE(S): CASREACT 144:192275; MARPAT 144:192275
GI



I



II

AB The invention is related to substituted quinazolinone derivs. I [R1 = (un)substituted pyrrolidin-3-yl, piperidin-3-yl, morpholin-4-yl, etc.; R2 = H, (un)substituted cyclo/alkyl, pyridinyl, Ph, etc.; R3 = H, halo, haloalkyl, (un)substituted Ph, alkyl, etc.; L = a bond, O, CO, S, SO2, NHSO2, NH and derivs., etc.; X = (CH2)m; m = 0-2; Y = (CH2)n; n = 1-2; p = 0-2; with provisos], and their pharmaceutically acceptable salts, and their compns., and methods for treating diabetes, obesity and related disorders, and regulation of glucose homeostasis and food intake (e.g., stimulation and suppression) (no data). The invention is also related to the preparation of quinazolinones I. Five biol. tests are given (no data). Thus, II•TFA was prepared by amination of 5-fluoro-2-nitrobenzoic acid with N-methylbutylamine, reduction of the nitro compound, cyclocondensation with o-anisoyl chloride, reaction with tert-Bu 3-(aminomethyl)piperidine-1- carboxylate (intermediate not isolated), and Boc-deprotection in the presence of TFA.

L66 ANSWER 8 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 8
ACCESSION NUMBER: 2005:1260632 ZCAPLUS Full-text
DOCUMENT NUMBER: 144:22916
TITLE: Preparation of anilino-heteroaryl-pyrazoles useful for the treatment of diabetes
INVENTOR(S): Cantin, Louis-David; Ma, Xin; Akuche, Christiana; Liang, Sidney X.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005112923	A2	20051201	WO 2005-US17889		20050520
WO 2005112923	A3	20060914			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2567352	A1	20051201	CA 2005-2567352		20050520
EP 1750698	A2	20070214	EP 2005-756060		20050520
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
JP 2007538102	T	20071227	JP 2007-527506		20050520
US 20080009531	A1	20080110	US 2006-596959		20061117
PRIORITY APPLN. INFO.:			US 2004-573066P	P	20040520
			WO 2005-US17889	W	20050520

OTHER SOURCE(S): CASREACT 144:22916; MARPAT 144:22916

GI



I



II

AB Title compds. I [R1 = H, alkyl, alkenyl, alkynyl, etc.; Het = thienyl, furyl, oxazolyl, etc.; R2 = alkyl, cycloalkyl, haloalkyl, etc.; R3 = alkyl, alkoxy, alkylthio, etc.; n = 0-3; X = CO2R4; R4 = H, alkyl, benzyl, etc.] are prepared For instance, II is prepared by the coupling of Me 2-[[4-bromo-3-methyl-1-(2-methylphenyl)-1H-pyrazol-5-yl]amino]-5- methoxybenzoate (preparation given) and 3-thiopheneboronic acid (DMF, (Ph3P)4Pd, Na2CO3, 150°, 15 min) in 23% yield. I are useful in the treatment of diabetes and syndrome X [no data].

L66 ANSWER 9 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 9
ACCESSION NUMBER: 2005:963796 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:266916
TITLE: Preparation of heteroarylaminopyrazoles for the treatment of diabetes
INVENTOR(S): Rudolph, Joachim; Wickens, Philip; Chuang, Chih-Yuan; Chen, Libing; Magnuson, Steven; Olague, Alan; Qi, Ning
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 78 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050192294	A1	20050901	US 2005-64700	20050224
AU 2005220723	A1	20050922	AU 2005-220723	20050224
CA 2557527	A1	20050922	CA 2005-2557527	20050224
WO 2005086656	A2	20050922	WO 2005-US5794	20050224
WO 2005086656	A3	20051229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1720863	A2	20061115	EP 2005-723606		20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR					
CN 1946715	A	20070411	CN 2005-80012855		20050224
BR 2005008051	A	20070717	BR 2005-8051		20050224
JP 2007525513	T	20070906	JP 2007-500954		20050224
MX 2006PA08833	A	20061030	MX 2006-PA8833		20060804
IN 2006DN04570	A	20070824	IN 2006-DN4570		20060808
NO 2006004325	A	20061122	NO 2006-4325		20060925
PRIORITY APPLN. INFO.:			US 2004-548331P	P	20040227
			US 2004-572906P	P	20040520
			WO 2005-US5794	W	20050224

OTHER SOURCE(S): CASREACT 143:266916; MARPAT 143:266916
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [substituted Het ring = II-VI; R = H, alkyl; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, alkyl, etc.; R3 = alkyl, cycloalkyl, haloalkyl, etc.; R4 = alkyl, alkoxy, alkylthio, etc.; n = 0-3; X = CO2R7, CONR5R6, SO2NH2; R5 = H, alkyl, Ph, etc.; R6 = H, alkyl; or NR5R6 = piperidine, morpholine, etc.; R7 = H, alkyl, benzyl, etc.; with the provisos], useful for treating diabetes and related disorders, were prepared E.g., a 2-step synthesis of VII, starting from 4,4-dimethyl-3-oxopentanenitrile and (2-methylphenyl)hydrazine hydrochloride, was given. The representative compds. I significantly reduced blood glucose levels relative to the vehicle following the i.p. glucose tolerance test in rats (no specific data given). The pharmaceutical compns. comprising the compound I are disclosed.

L66 ANSWER 10 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2004:995905 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:6415
TITLE: Preparation of indoleacetic acids for the treatment of diabetes and related diseases.
INVENTOR(S): Ma, Xin; Cantin, Louis-David; Choi, Soongyu; Clark, Roger; Rentemann, Martin; Rudolph, Joachim; Lavoie, Rico; Zhang, Zhonghua
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004098498	A2	20041118	WO 2004-US12959		20040428
WO 2004098498	A3	20050728			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2523245	A1	20041118	CA 2004-2523245		20040428
EP 1620088	A2	20060201	EP 2004-750750		20040428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2006524709	T	20061102	JP 2006-513366		20040428
US 20060264486	A1	20061123	US 2005-555024		20051026
PRIORITY APPLN. INFO.:			US 2003-466143P	P	20030428
			WO 2004-US12959	W	20040428

OTHER SOURCE(S): MARPAT 142:6415

GI



I

AB Title compds. [I; R1 = H, alkyl, PhCH2; R2, R3 = H, alkyl; Y = O, NR5; R5 = H, alkyl, cycloalkylalkyl; n = 2-4; Ar = (substituted) Ph, heteroaryl], were prepared for the treatment of diseases such as diabetes and metabolic syndrome X (no data). Thus, 1-(2-bromoethoxy)-4-ethyl-2-methoxybenzene (preparation given), Me 2-(5-hydroxyindol-1-yl)propionate (preparation given) and Cs2CO3 were heated at 140° in DMF for 3 h followed by addition of HCl to pH 2 to give 8% 2-[5-[2-(4-ethyl-2-methoxyphenoxy)ethoxy]indol-1- yl]propionic acid.

L66 ANSWER 11 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 11

ACCESSION NUMBER:	2004:565052 ZCAPLUS Full-text
DOCUMENT NUMBER:	141:123483
TITLE:	Preparation of indaneacetic acid derivatives and their use as pharmaceutical agents
INVENTOR(S):	Cantin, Louis-David; Choi, Soongyu; Clark, Roger B.; Hentemann, Martin F.; Ma, Xin; Rudolph, Joachim; Liang, Sidney X.; Akuche, Christiana; Lavoie, Rico C.; Chen, Libing; Majumdar, Dyuti; Wickens, Philip L.
PATENT ASSIGNEE(S):	Bayer Pharmaceuticals Corporation, USA
SOURCE:	PCT Int. Appl., 230 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058174	A2	20040715	WO 2003-US40842	20031219
WO 2004058174	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2510793	A1	20040715	CA 2003-2510793	20031219
AU 2003299790	A1	20040722	AU 2003-299790	20031219
EP 1578715	A2	20050928	EP 2003-800063	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516251	T	20060629	JP 2004-563903	20031219
US 20060084680	A1	20060420	US 2005-537630	20050603

PRIORITY APPLN. INFO.: US 2002-435310P P 20021220
WO 2003-US40842 W 20031219

OTHER SOURCE(S): MARPAT 141:123483
GI



I



II

AB The title compds. [I; R1, R2 = H, alkyl, cycloalkyl; L = (CH2)mX, Y(CH2)nX, etc.; X = O, S, SO, SO2, Y = O, S, SO, SO2, (un)substituted NH; m = 1-3; n = 2-4; Ar = (un)substituted Ph, 5-6 membered heteroaryl containing up to there N atoms] which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, coupling Et {(1S)-5-[3-(4-bromo-2- methoxyphenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl}acetate (preparation given) with 3-thiopheneboronic acid in the presence of PdCl2(dppf).CH2Cl2, NaHCO3 in DME/H2O followed by treatment of the resulting ester with LiOH afforded (1S)-II.

L66 ANSWER 12 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 12
ACCESSION NUMBER: 2004:493698 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:54329
TITLE: Preparation of anilinopyrazoles for the treatment of diabetes
INVENTOR(S): Rudolph, Joachim; Cantin, Louis-David; Magnuson, Steven; Bullock, William; Bullion, Ann-Marie; Chen, Libing; Chuang, Chih-Yuan; Liang, Sidney; Majumdar, Dyuti; Ogutu, Herbert; Olague, Alan; Qi, Ning; Wickens, Philip L.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004050651	A1	20040617	WO 2003-US37829		20031125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040157904	A1	20040812	US 2003-719485		20031121
US 7265144	B2	20070904			
CA 2507186	A1	20040617	CA 2003-2507186		20031125
AU 2003297565	A1	20040623	AU 2003-297565		20031125
EP 1567517	A1	20050831	EP 2003-812454		20031125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016723	A	20051018	BR 2003-16723		20031125
CN 1717401	A	20060104	CN 2003-80104353		20031125
JP 2006510728	T	20060330	JP 2004-570952		20031125
MX 2005PA04621	A	20050608	MX 2005-PA4621		20050429
IN 2005DN01784	A	20070202	IN 2005-DN1784		20050502
ZA 2005005055	A	20060927	ZA 2005-5055		20050622
US 20080064734	A1	20080313	US 2007-897620		20070831
PRIORITY APPLN. INFO.:			US 2002-429917P	P	20021127
			US 2003-498214P	P	20030827
			US 2003-719485	A3	20031121
			WO 2003-US37829	W	20031125

OTHER SOURCE(S): MARPAT 141:54329
GI



I

AB The title compds. [I; R = H, alkyl; R1 = H, alkyl, alkoxyalkyl, etc.; R2 = H, halo, alkyl, alkoxyalkyl, etc.; R3 = alkyl, cycloalkyl, (un)substituted benzyl, etc.; R4 = alkyl, alkoxyalkyl, alkoxy, halo, etc.; n = 0-4; X = CO2R8, CONR5R6, SO2NHR7, oxadiazolyl; R5 = H, alkyl, benzyl, etc.; NR5R6 = piperidino, morpholino, thiomorpholino, piperazino; R7 = H, Me; R8 = H, alkyl, benzyl, etc.; with provisos], useful for treating diabetes and related disorders, were prepared and formulated. Thus, reacting 2-bromo-5-methoxybenzoic acid with 5-amino-3-tert-butyl-1-methylpyrazole in the presence of K2CO3 and Cu(OAc)2 in DMF afforded 31% I [R = H; R1 = tert-Bu; R2 = H; R3 = Me; R4 = 4-OMe; X = 2-(CO2H)]. The compds. I were found to be active in the insulin secretion from INS-1 cells assay (measured at 10 μM).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 13 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 13

ACCESSION NUMBER: 2004:493697 ZCAPLUS Full-text

DOCUMENT NUMBER: 141:54328

TITLE: Preparation of anilinopyrazoles for the treatment of diabetes

INVENTOR(S): Rudolph, Joachim; Cantin, Louis-David; Magnuson, Steven; Bullock, William; Bullion, Ann-Marie; Chen, Libing; Chuang, Chih-Yuan; Liang, Sidney; Majumdar, Dyuti; Ogutu, Herbert; Olague, Alan; Qi, Ning; Wickens, Philip L.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004050650	A1	20040617	WO 2003-US37578		20031121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003295890	A1	20040623	AU 2003-295890		20031121
US 20040157904	A1	20040812	US 2003-719485		20031121
US 7265144	B2	20070904			
CN 1717401	A	20060104	CN 2003-80104353		20031125
ZA 2005005055	A	20060927	ZA 2005-5055		20050622
US 20080064734	A1	20080313	US 2007-897620		20070831
PRIORITY APPLN. INFO.:			US 2002-429917P	P	20021127
			US 2003-498214P	P	20030827
			US 2003-719485	A3	20031121
			WO 2003-US37578	W	20031121

OTHER SOURCE(S): MARPAT 141:54328

GI



I

AB The title compds. [I; R = H, alkyl; R1 = H, alkyl, alkoxyalkyl, etc.; R2 = H, halo, alkyl, alkoxyalkyl, etc.; R3 = alkyl, cycloalkyl, (un)substituted benzyl, etc.; R4 = alkyl, alkoxyalkyl, alkoxy, halo, etc.; n = 0-4; X = CO2R8, CONR5R6, SO2NHR7, oxadiazolyl; R5 = H, alkyl, benzyl, etc.; NR5R6 = piperidino, morpholino, thiomorpholino, piperazino; R7 = H, Me; R8 = H, alkyl, benzyl, etc.; with provisos], useful for treating diabetes and related disorders, were prepared and formulated. Thus, reacting 2-bromo-5-methoxybenzoic acid with 5-amino-3-tert-butyl-1-methylpyrazole in the presence of K2CO3 and Cu(OAc)2 in DMF afforded 31% I [R = H; R1 = tert-Bu; R2 = H; R3 = Me; R4 = 4-OMe; X = 2-(CO2H)]. The compds. I were found to be active in the insulin secretion from INS-1 cells assay (measured at 10 μM).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 14 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 14

ACCESSION NUMBER: 2004:101148 ZCAPLUS Full-text

DOCUMENT NUMBER: 140:163867

TITLE: Preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivatives as antidiabetic agents

INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Chuang, Chih-Yuan; Dai, Miao; Hentemann, Martin F.; Kumarasinghe, Ellalahewage; Liang, Sidney X.; Lowe, Derek B.; Shelekhin, Tatiana E.; Wang, Yamin; Zhang, Chengzhi; Zhang, Hai-Jun; Zhao, Qian

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 204 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011446	A1	20040205	WO 2003-US23342	20030725

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003263814 A1 20040216 AU 2003-263814 20030725
PRIORITY APPLN. INFO.: US 2002-399095P P 20020726
WO 2003-US23342 W 20030725
OTHER SOURCE(S): MARPAT 140:163867
GI



I



II

AB Title compds., e.g., I [X = O, S; n = 1-3; R1 = carboxy, carboxamide, alkylamino, etc.; R2-3 = H, F, alkyl; R4-6 = H, alkyl; R7 = H, alkoxy, OH, etc.; R9 = H, Br, Cl, I, alkyl, etc.; R10 = H, OSO2CF3, etc.; R11 = H, alkyl, etc.; R12 = naphthyl, pyridyl, etc.] are prepared For instance, Et (S)-[5-hydroxy-2,3-dihydro-1H-inden-1-yl]acetate (preparation given) is coupled to 4-chloromethyl-5-methyl-2-phenyloxazole (preparation given; DMF, K2CO3, 3 h, 80°) to give II. I are useful in the treatment of diseases such as diabetes, diabetes-related disorders, obesity, hyperlipidemia and cardiovascular diseases.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 15 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 15
ACCESSION NUMBER: 2003:855915 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:350727
TITLE: Preparation of indaneacetic acid derivatives for treating diabetes or diabetes-related disorders
INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Kumarasinghe, Ellalahewage; Chuang, Chih-Yuan; Liang, Sidney X.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089418	A1	20031030	WO 2003-US11725	20030416

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CN 1854118	A	20061101	CN 2006-10004609	20020725
CA 2482714	A1	20031030	CA 2003-2482714	20030416
AU 2003221960	A1	20031103	AU 2003-221960	20030416
EP 1497271	A1	20050119	EP 2003-718423	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526834	T	20050908	JP 2003-586139	20030416
US 20050107392	A1	20050519	US 2004-506270	20040830
US 20050075338	A1	20050407	US 2004-949119	20040922
US 7112597	B2	20060926		
US 20060205723	A1	20060914	US 2006-429136	20060505
US 7358386	B2	20080415		

PRIORITY APPLN. INFO.:	US 2002-373048P	P	20020416
	US 2001-308500P	P	20010727
	CN 2002-818676	A3	20020725
	US 2002-205839	A1	20020725
	WO 2003-US11725	W	20030416
	US 2004-949119	A3	20040922

OTHER SOURCE(S): MARPAT 139:350727

GI



I



II

AB The title compds. [I; R, R1 = H, alkyl; R2 = H, alkyl, (un)substituted Ph; R3 = H, halo, NO2, etc.; R4 = cycloalkyl, alkenyl, NO2, etc.; X = O, S], useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. E.g., a multi-step synthesis of (1S)-II, was given.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 16 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:861834 ZCAPLUS Full-text
TITLE: Indole acetic acid derivatives incorporating [(thiazolyl/oxazolyl)-phenoxy/pyridyloxy] tail groups - novel, potent PPAR alpha/gamma/delta triple agonists: Synthesis, SAR, and in vivo efficacy
AUTHOR(S): Ma, Xin; Bentemann, Martin; Rudolph, Joachim; Bullock, William H.; Burns, Michael; Cantin, Louis-David; Chen, Libing; Choi, Soongyu; Clark, Roger; Claus, Thomas; Dela Cruz, Fernando E.; Daly, Michelle; Ehrgott, Frederick J.; Iwuagwu, Christiana I.; Johnson, Jeffrey S.; Kumarasinghe, Ellalahewage; Lavoie, Rico; Liang, Sidney; Livingston, James N.; Majumdar, Dyuti; Nophsker, Michelle; Ogutu, Herbert; Schoenleber, Robert W.; Shapiro, Jeffrey; Sidhu, Kanwar; Town, Christopher; Tomlinson, Susan; Wickens, Philip L.; Yang, Ling; Zhang, Zhonghua; Tsutsumi, Manami
CORPORATE SOURCE: Department of Chemistry Research, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10-14, 2006 (2006) , MEDI-379. American Chemical Society: Washington, D. C.
CODEN: 69IHRD
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)
LANGUAGE: English
AB The nuclear receptors PPAR gamma and PPAR alpha are therapeutic targets for insulin resistance/hyperglycemia and dyslipidemia, resp. Clin. successes of the single-action drugs that modulate these targets individually had drawn significant interest in a multi-targeted single-agent therapy to treat metabolic syndrome. Moreover, with increased understanding of the role of PPAR delta for its dual benefit for both dyslipidemia and insulin resistance, potential synergistic effects of activating all three PPAR isoforms are of high interest. Here we report a new class of PPAR triple agonists exemplified by the generic indoleacetic acid (I). Through structure-activity relationship studies, in vivo characterizations, and ADME profiling, compds. with similar potency on glucose-lowering and lipid endpoints possessing favorable drug properties were identified. Leads in this class normalize blood glucose while demonstrating lipid modulating effects in a diverse array of animal models.

L66 ANSWER 17 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:861833 ZCAPLUS Full-text
TITLE: Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups: A new class of PPAR gamma/delta and PPAR alpha/gamma/delta agonists
AUTHOR(S): Cantin, Louis-David; Liang, Sidney; Ogutu, Herbert; Iwuagwu, Christiana I.; Bullock, William H.; Burns, Michael; Clark, Roger; Claus, Thomas; dela Cruz, Fernando E.; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; Nophsker, Michelle; Schoenleber, Robert W.; Shapiro, Jeffrey; Town, Christopher; Yang, Ling; Tsutsumi, Manami; Ma, Xin
CORPORATE SOURCE: Department of Chemistry Research, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Abstracts of Papers, 232nd ACS National Meeting, San

Francisco, CA, United States, Sept. 10-14, 2006 (2006) , MEDI-378. American Chemical Society: Washington, D. C.
CODEN: 69IHRD
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)
LANGUAGE: English
AB Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications. The indane acetic acid structural motif has proven useful in the generation of potent and tunable PPAR ligands. Modification of the subtituents on the linker and the heterocycle allowed for the modulation of the PPAR alpha activity, while maintaining the PPAR delta and PPAR gamma activity. Compound 2 was further evaluated in vivo, where it displayed the desired reduction of glucose levels and increase in HDL levels in various animal models.

L66 ANSWER 18 OF 19 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:861832 ZCAPLUS Full-text
TITLE: Indanylacetic acids carrying 4-thiazolyl/oxazolyl-phenyl tail groups, a new class of balanced PPAR alpha/gamma/delta triple agonists: Synthesis, SAR and in vivo efficacy
AUTHOR(S): Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Choi, Soongyu; Claus, Thomas; Dela Cruz, Fernando E.; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; Nophsker, Michelle; Schoenleber, Robert W.; Shapiro, Jeffrey; Tomlinson, Susan; Town, Christopher; Yang, Ling; Tsutsumi, Manami; Ma, Xin
CORPORATE SOURCE: Department of Chemistry Research, Bayer Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10-14, 2006 (2006) , MEDI-377. American Chemical Society: Washington, D. C.
CODEN: 69IHRD
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)
LANGUAGE: English
AB Compds. that simultaneously activate the three major peroxisome proliferator-activated receptors (PPAR) alpha, gamma, and delta, hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic syndrome. Previous studies identified the indanylacetic acid moiety as a preferred and tunable PPAR agonist head group. Here we report the synthesis and SAR studies of new aryl tail group derivs. While most of the tail group modifications imparted potent PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required systematic optimization. This effort led to the discovery of 4-thiazolyl/oxazolyl-Ph derivs. (I) with potent and balanced PPAR alpha/gamma/delta triple agonistic activity. An optimized candidate from this series was found to exhibit excellent ADME properties and superior therapeutic potential compared to established PPAR gamma and alpha, gamma activating agents by favorably modulating lipid levels in hApoA1 mice and hyperlipidemic hamsters, while normalizing glucose levels in diabetic rodent models.

L66 ANSWER 19 OF 19 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER: 2008:393080 BIOSIS Full-text
DOCUMENT NUMBER: PREV200800393079
TITLE: Anilinopyrazole derivatives useful for the treatment of diabetes.
AUTHOR(S): Anonymous; Rudolph, Joachim [Inventor]; Cantin, Louis-David [Inventor]; Magnuson, Steven [Inventor]; Bullock, William [Inventor]; Bullion, Ann-Marie [Inventor]; Chen, Libing [Inventor]; Chuang, Chih-Yuan [Inventor]; Liang, Sidney [Inventor]; Majumdar, Dyuti [Inventor]; Ogutu, Herbert [Inventor]; Olague, Alan [Inventor]; Qi, Ning [Inventor]; Wickens, Philip L. [Inventor]
CORPORATE SOURCE: Guilford, CT USA
ASSIGNEE: Bayer Pharmaceuticals Corporation
PATENT INFORMATION: US 07265144 20070904
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (SEP 4 2007)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Jul 2008
Last Updated on STN: 16 Jul 2008
ABSTRACT:The present invention relates to anilinopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.
NAT. PATENT. CLASSIF.:514406000
CONCEPT CODE: Pathology - Therapy 12512
Metabolism - General metabolism and metabolic pathways 13002
Metabolism - Metabolic disorders 13020
Endocrine - General 17002
Endocrine - Pancreas 17008
Pharmacology - General 22002
Pharmacology - Endocrine system 22016
INDEX TERMS: Major Concepts
Pharmacology; Metabolism; Clinical Endocrinology (Human Medicine, Medical Sciences)
INDEX TERMS: Diseases
diabetes: endocrine disease/pancreas, metabolic disease, drug therapy
Diabetes Mellitus (MeSH)
INDEX TERMS: Chemicals & Biochemicals
anilinopyrazole derivatives: antidiabetic-drug

```
=> file registry
FILE 'REGISTRY' ENTERED AT 17:19:29 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 JUL 2008  HIGHEST RN 1035004-20-6
DICTIONARY FILE UPDATES:  20 JUL 2008  HIGHEST RN 1035004-20-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading L1.str
```




```
chain nodes :
10  11  12  13  14  15  23
ring nodes :
```

```
1  2  3  4  5  6  7  8  9  16  17  18  19  20  21
chain bonds :
7-23  10-12  10-11  10-23  13-14  14-15  15-19
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  16-17  16-21  17-18  18-19  19-20
20-21
exact/norm bonds :
5-7  6-9  7-8  7-23  8-9  10-12  10-11  10-23  13-14  14-15  15-19
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom
19:Atom  20:Atom  21:Atom
22:CLASS  23:CLASS


Uploading L10.str
```




```
chain nodes :
1  2  3  4  5  6  13  16
ring nodes :
7  8  9  10  11  12
chain bonds :
1-3  1-2  1-13  4-5  4-16  5-6  6-10  13-16
ring bonds :
7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
1-3  1-2  1-13  4-5  4-16  5-6  6-10  13-16
```

```
normalized bonds :
7-8  7-12  8-9  9-10  10-11  11-12


G1:O,S,N

G2:O,S

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:Atom  8:Atom  9:Atom
10:Atom
11:Atom  12:Atom  13:CLASS  16:Atom
Generic attributes :
16:
Saturation             : Unsaturated
Number of Carbon Atoms : 7 or more
Type of Ring System    : Polycyclic




=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 17:19:33 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 21 Jul 2008  VOL 149 ISS 4
FILE LAST UPDATED: 20 Jul 2008  (20080720/ED)

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L4
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L3          363 SEA FILE=REGISTRY SSS FUL L1
L4            6 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L3
```

```
=> file babs
FILE 'BABS' ENTERED AT 17:19:42 ON 21 JUL 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE LAST UPDATED: 14 JUL 2008       <20080714/UP>
FILE COVERS 1980 TO DATE.

=> d stat que L8
L8            1 SEA FILE=BABS ABB=ON  PLU=ON  6653078/BABSAN


=> file beilstein
FILE 'BEILSTEIN' ENTERED AT 17:20:00 ON 21 JUL 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
*** FILE CONTAINS 10.322,808  SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

*********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.               *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE  *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE         *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                       *
* FOR PRICE INFORMATION SEE HELP COST                               *
*********************************************************************

>>> Price change as of January 1st, 2008: Connect Time and Structure
    Search fees re-introduced. See NEWS and HELP COST <<<

=> d stat que L16
L1             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L6          161 SEA FILE=BEILSTEIN SSS FUL L1
L7           98 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L6 AND BABSAN/FA
L10            STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *
```

```
Structure attributes must be viewed using STN Express query preparation.
L12         161 SEA FILE=BEILSTEIN SUB=L6 SSS FUL L10
L13          63 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L12 NOT L7
L16          63 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L13 AND 2007?/DED


=> file wpix
FILE 'WPIX' ENTERED AT 17:20:17 ON 21 JUL 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED:                        15 JUL 2008   <20080715/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE:     200845      <200845/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of
    March 2008. No update date (UP) has been created for the
    reclassified documents, but they can be identified by
    20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC,
    20071130/UPIC and 20080401/UPIC.
    ECLA reclassifications to April and US national classifications to
    the end of January 2008 have also been loaded. Update dates
    20080401/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Please note that the COPYRIGHT notification has changed <<<

'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d stat que L27
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L26          41 SEA FILE=WPIX SSS FUL L1
L27           1 SEA FILE=WPIX ABB=ON  PLU=ON  L26/DCR


=> file marpat
FILE 'MARPAT' ENTERED AT 17:20:25 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 2 (20080718/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987
```

```
MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US  20080139418 12 JUN 2008
DE 102006057118 05 JUN 2008
EP      1930004 11 JUN 2008
JP   2008127427 05 JUN 2008
WO   2008070241 12 JUN 2008
GB      2443936 21 MAY 2008
FR      2909090 30 MAY 2008
RU      2325390 27 MAY 2008
CA      2568954 27 MAY 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT
have increased from 100,000 to 200,000 for both on-line and batch
searches.  For more information on MARPAT search limits, type HELP
SLIMITS at an arrow prompt.

=> d stat que L29
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L29          26 SEA FILE=MARPAT SSS FUL L1

100.0% PROCESSED    94044 ITERATIONS  (     1 INCOMPLETE)       26 ANSWERS
SEARCH TIME: 00.00.48



=> dup rem L4 L8 L27 L29
FILE 'ZCAPLUS' ENTERED AT 17:20:46 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BABS' ENTERED AT 17:20:46 ON 21 JUL 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'WPIX' ENTERED AT 17:20:46 ON 21 JUL 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'MARPAT' ENTERED AT 17:20:46 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)
PROCESSING COMPLETED FOR L4
PROCESSING COMPLETED FOR L8
PROCESSING COMPLETED FOR L27
PROCESSING COMPLETED FOR L29
L67          29 DUP REM L4 L8 L27 L29 (5 DUPLICATES REMOVED)
                ANSWERS '1-6' FROM FILE ZCAPLUS
                ANSWERS '7-29' FROM FILE MARPAT

=> d ibib abs hitstr L67 1-6; d ibib abs qhit L67 7-29; file beilstein; d stat que
L22; d stat que L16; d ide allref L16 1,20,40,50,60
```

L67 ANSWER 1 OF 29 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2007:1145223 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:448535
TITLE: Preparation of substituted bicyclic compounds for inhibiting the production of prostaglandin or leukotriene
INVENTOR(S): Matsumoto, Akiko; Shoda, Motoshi; Kuriyama, Hiroshi
PATENT ASSIGNEE(S): Asahi Kasei Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 624pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007114213	A1	20071011	WO 2007-JP56791	20070329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2006-95008 A 20060330
OTHER SOURCE(S): MARPAT 147:448535
GI



I



II

AB Title compds. I [the dotted line accompanied by a solid line = single or double bond; further details on the dotted line accompanied by a solid line are given; Link = single bond or (un)saturated hydrocarbon; W = single bond, methylene, oxygen atom , etc.; Rs = -D-Rx or -N(Ry)(Rz); D = single bond, oxygen, sulfur atom, etc.; Rx = saturated alkyl, R1-Aa-, etc; Aa = single bond, alkylene or alkenylene (wherein alkylene and alkenylene are optionally substituted with alkyl); R1 = saturated cycloalkyl or saturated condensed cycloalkyl (wherein R1 is optionally substituted with alkyl); Rz = Rx, Me, Et, etc.; Ry = H, alkyl, -A6-Qp, etc.; A6 = single bond or methylene; Qp = Ph (optionally substituted with T1); T1 = saturated alkyl, hydroxy, fluoro, etc.; one of V1 and V2 is Zx, the other is AR; Zx = H, saturated alkyl, fluoro, etc.; AR = partially or completely unsatd. condensed carbobicycle or heterobicycle (optionally substituted with Xa); Xa = saturated alkyl, saturated cycloalkyl, oxo, etc.; Y = H, alkyl, -(CH2)mN(R18)(R19), etc.; m = 2, 3; R18, R19 = Me, Et or propyl; R18 and R19, together with the nitrogen atom to which they are attached, may form a N-containing cycloalkyl or morpholino group] or salts thereof were prepared Thus, a multi-step synthesis of compound II, starting from 5-hydroxy-1-indanone, was given. The exemplified compound II inhibited the production of PGE2 by ≥50% at 1.0 μM. Compds. I are claimed useful for the treatment of inflammation, autoimmune disease, etc.

IT 952035-95-9P 952035-97-1P 952035-99-3P
952037-17-1P 952037-19-3P 952037-21-7P
952321-54-9P 952321-56-1P 952322-62-2P
952322-64-4P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of substituted bicyclic compds. for inhibiting production of prostaglandin or leukotriene)

RN 952035-95-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952035-97-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952035-99-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952037-17-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]- (CA INDEX NAME)



RN 952037-19-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]- (CA INDEX NAME)



RN 952037-21-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]- (CA INDEX NAME)



RN 952321-54-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1-methyl-1H-indol-5-yl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952321-56-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(2-phenoxyethoxy)-6-(6-quinolinyl)- (CA INDEX NAME)



RN 952322-62-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-[2-

(phenylthio)ethoxy]- (CA INDEX NAME)



RN 952322-64-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]- (CA INDEX NAME)



IT 952037-75-1P 952037-76-2P 952037-77-3P
952038-19-6P 952038-20-9P 952038-21-0P
952038-77-6P 952038-78-7P 952038-79-8P
952039-21-3P 952039-22-4P 952039-23-5P
952330-64-2P 952330-66-4P 952331-31-6P
952331-32-7P 952333-52-7P 952333-54-9P
952334-94-0P 952334-96-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted bicyclic compds. for inhibiting production of prostaglandin or leukotriene)

RN 952037-75-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952037-76-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952037-77-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952038-19-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952038-20-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952038-21-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952038-77-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952038-78-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952038-79-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952039-21-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952039-22-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952039-23-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952330-64-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1-methyl-1H-indol-5-yl)-5-(2-phenoxyethoxy)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952330-66-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(2-phenoxyethoxy)-6-(6-quinolinyl)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952331-31-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-[2-(phenylthio)ethoxy]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952331-32-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952333-52-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1-methyl-1H-indol-5-yl)-5-(2-phenoxyethoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952333-54-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(2-phenoxyethoxy)-6-(6-quinolinyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952334-94-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-[2-(phenylthio)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952334-96-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 952026-87-8P 952026-89-0P 952026-91-4P
952026-93-6P 952026-95-8P 952028-93-2P
952028-97-6P 952028-99-8P 952029-01-5P
952033-20-4P 952033-22-6P 952033-24-8P
952033-26-0P 952034-70-7P 952034-72-9P
952034-74-1P 952034-76-3P 952035-94-8P
952035-96-0P 952035-98-2P 952037-16-0P
952037-18-2P 952037-20-6P 952321-51-6P
952321-53-8P 952321-55-0P 952322-61-1P
952322-63-3P 952323-30-7P 952324-53-7P
952325-79-0P 952327-29-6P 952327-71-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted bicyclic compds. for inhibiting production of prostaglandin or leukotriene)

RN 952026-87-8 ZCAPLUS
CN Acetic acid, 2-[6-(1-ethyl-1H-indol-5-yl)-2,3-dihydro-5-(2-phenoxyethoxy)-

1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952026-89-0 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952026-91-4 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952026-93-6 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952026-95-8 ZCAPLUS

CN Acetic acid, 2-[2,3-dihydro-6-(6-isoquinolinyl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952028-93-2 ZCAPLUS

CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952028-97-6 ZCAPLUS

CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952028-99-8 ZCAPLUS

CN Acetic acid, 2-[6-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952029-01-5 ZCAPLUS

CN Acetic acid, 2-[2,3-dihydro-5-[2-(phenylthio)ethoxy]-6-(6-quinolinyl)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952033-20-4 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952033-22-6 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952033-24-8 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952033-26-0 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-5-(2-phenoxyethoxy)-4-(6-quinolinyl)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952034-70-7 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952034-72-9 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952034-74-1 ZCAPLUS
CN Acetic acid, 2-[4-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952034-76-3 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-5-[2-(phenylthio)ethoxy]-4-(6-quinolinyl)-1H-inden-1-ylidene]-, ethyl ester (CA INDEX NAME)



RN 952035-94-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952035-96-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952035-98-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952037-16-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 952037-18-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 952037-20-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 952321-51-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952321-53-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1-methyl-1H-indol-5-yl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952321-55-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(2-phenoxyethoxy)-6-(6-quinolinyl)-, ethyl ester (CA INDEX NAME)



RN 952322-61-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-[2-(phenylthio)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 952322-63-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-, ethyl ester (CA INDEX NAME)



RN 952323-30-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-chloro-2,3-dihydro-6-(2-naphthalenyl)-5-(2-

phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952324-53-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-chloro-2,3-dihydro-6-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952325-79-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-bromo-2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952327-29-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-bromo-6-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-(2-phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



RN 952327-71-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-methyl-6-(2-naphthalenyl)-5-(2-

phenoxyethoxy)-, ethyl ester (CA INDEX NAME)



IT 952026-88-9P 952026-90-3P 952026-92-5P
952026-94-7P 952026-96-9P 952028-95-4P
952028-98-7P 952029-00-4P 952029-02-6P
952033-21-5P 952033-23-7P 952033-25-9P
952033-27-1P 952034-71-8P 952034-73-0P
952034-75-2P 952034-77-4P 952321-52-7P
952323-31-8P 952324-54-8P 952325-80-3P
952327-30-9P 952327-72-9P 952330-60-8P
952330-62-0P 952333-48-1P 952333-50-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted bicyclic compds. for inhibiting production of prostaglandin or leukotriene)

RN 952026-88-9 ZCAPLUS
CN Acetic acid, 2-[6-(1-ethyl-1H-indol-5-yl)-2,3-dihydro-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952026-90-3 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952026-92-5 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952026-94-7 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952026-96-9 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(6-isoquinolinyl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952028-95-4 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952028-98-7 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-6-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952029-00-4 ZCAPLUS
CN Acetic acid, 2-[6-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952029-02-6 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-5-[2-(phenylthio)ethoxy]-6-(6-quinolinyl)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952033-21-5 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-4-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952033-23-7 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952033-25-9 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952033-27-1 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-5-(2-phenoxyethoxy)-4-(6-quinolinyl)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952034-71-8 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-5-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952034-73-0 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-4-(1-methyl-1H-indol-6-yl)-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952034-75-2 ZCAPLUS
CN Acetic acid, 2-[4-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-[2-(phenylthio)ethoxy]-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952034-77-4 ZCAPLUS
CN Acetic acid, 2-[2,3-dihydro-5-[2-(phenylthio)ethoxy]-4-(6-quinolinyl)-1H-inden-1-ylidene]- (CA INDEX NAME)



RN 952321-52-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952323-31-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-chloro-2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952324-54-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-chloro-2,3-dihydro-6-(1-methyl-1H-indazol-5-yl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952325-80-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-bromo-2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952327-30-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-bromo-6-(1-ethyl-1H-indazol-5-yl)-2,3-dihydro-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952327-72-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-4-methyl-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)



RN 952330-60-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)-, ethyl ester, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952330-62-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952333-48-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 952333-50-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(2-naphthalenyl)-5-(2-phenoxyethoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 2 OF 29 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2007:702766 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:118046
TITLE: Fluorenes and carbazoles as ligands of the EP2 receptor
INVENTOR(S): Braeuer, Nico; Buchmann, Bernd; Huwe, Christoph; Lindenthal, Bernhard; Langer, Gernot; Peters, Olaf; Schubert, Gerd; Bothe, Ulrich; Toschi, Luisella; Peters-Kottig, Michaele
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 120pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007071456	A1	20070628	WO 2006-EP12640	20061221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102005062741	A1	20070628	DE 2005-102005062741	20051222
US 20070197524	A1	20070823	US 2006-642975	20061221
PRIORITY APPLN. INFO.:			DE 2005-102005062741A	20051222
			US 2005-754186P P	20051228

OTHER SOURCE(S): MARPAT 147:118046

GI



I

AB Carbazole and fluorene derivs. (I) [R1 = O(CH)mOY; Y = (un)substituted 5 - 12-membered, mono- or bicyclic aryl or heteroaryl; Z = C or N; X = OH, NH2, O-alkyl, NH-alkyl, N-cycloalkyl, cycloamine, NHSO2-alkyl or (un)substituted (un)saturated cycloalkyl; m = 1 - 7; n = 1 - 4] were prepared as human EP2 receptor antagonists for treatment and prophylaxis of disorders connected to the EP2 receptor; and process for their preparation characterized in that a bromoalkyl side chain is inserted in a hydrofluorene or hydroxycarbazole derivs. I (R1 = OH; X = O-alkyl; Z, m, n are as defined above), following by introduction of an aryl ether and ester hydrolysis, was developed. Thus, (R/S)[2-[4-(3-hydroxyphenoxy)butoxy]-9H-fluore-9- yl]acetic acid prepared by reaction of 2-hydroxyfluoren-9-one with triethylphosphoacetate, following by olefin hydrogenation, alkylation with 2,4-dibromobutane, benzylation with resorcinol and ester hydrolysis showed the biol. activity IC50 = 6.4 measured by means of the cAMP antagonism test.

IT 943029-19-4P 943029-20-7P 943029-21-8P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fluorenes and carbazoles as EP2 receptor antagonists for treatment and prophylaxis of disorders connected to EP2 receptor)

RN 943029-19-4 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-(3-hydroxy-5-methoxyphenoxy)butoxy]- (CA INDEX NAME)



RN 943029-20-7 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-(3-hydroxyphenoxy)butoxy]- (CA INDEX NAME)



RN 943029-21-8 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-[3-(acetylamino)phenoxy]butoxy]- (CA INDEX NAME)



IT 943029-14-9P 943029-15-0P 943029-16-1P
943029-17-2P 943029-18-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fluorenes and carbazoles as EP2 receptor antagonists for treatment and prophylaxis of disorders connected to EP2 receptor)

RN 943029-14-9 ZCAPLUS
CN Acetic acid, 2-[2-[4-(3-methylphenoxy)butoxy]-9H-fluoren-9-ylidene]-, ethyl ester (CA INDEX NAME)



RN 943029-15-0 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-(3-hydroxy-5-methoxyphenoxy)butoxy]-, ethyl ester (CA INDEX NAME)



RN 943029-16-1 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-(3-hydroxyphenoxy)butoxy]-, ethyl ester (CA INDEX NAME)



RN 943029-17-2 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-[3-(acetylamino)phenoxy]butoxy]-, ethyl ester (CA INDEX NAME)



RN 943029-18-3 ZCAPLUS
CN 9H-Fluorene-9-acetic acid, 2-[4-(3-methylphenoxy)butoxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 3 OF 29 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2007:126146 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:379894
TITLE: Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α/γ/δ pan agonists: synthesis, structure-activity relationship, and in vivo efficacy
AUTHOR(S): Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Dela Cruz, Fernando E.; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; Schoenleber, Robert W.; Shapiro, Jeffrey; Yang, Ling; Tsutsumi, Manami; Ma, Xin
CORPORATE SOURCE: Bayer HealthCare Pharmaceuticals Corporation, West Haven, CT, 06516, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(5), 984-1000
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:379894
GI



I

AB Compds. that simultaneously activate the three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, gamma, and delta hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic syndrome. It was recently identified the indanylacetic acid moiety as a well-tunable PPAR agonist head group. Herein, the synthesis and structure-activity relationship (SAR) studies of aryl tail group derivs. that led to a class of potent PPAR pan agonists was reported. While most of the tail group modifications imparted potent PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required the introduction of new heterocyclic substituents that were not known in the PPAR literature. Systematic optimization led to the discovery of 4-thiazolyl-Ph derivs. with potent PPAR alpha/gamma/delta pan agonistic activity. From this series, the lead candidate I was found to exhibit excellent ADME properties and superior therapeutic potential compared to known PPAR gamma activating agents by favorably modulating lipid levels in hApoA1 mice and hyperlipidemic hamsters, while normalizing glucose levels in diabetic rodent models.
IT 724466-35-7 724466-37-9 724466-40-4
724466-44-8 724466-47-1 724466-50-6
724466-54-0 724466-55-1 724466-56-2
724466-57-3 724466-58-4 724466-60-8
724466-61-9 724466-62-0 724466-63-1
724466-64-2
RL: PAC (Pharmacological activity); BIOL (Biological study)
(comparison of PPAR α/δ agonistic activity of (benzisoxazolyloxypropyloxy)indanylacetic acids)
RN 724466-35-7 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-37-9 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-40-4 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-propyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-44-8 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-4-propyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-47-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-50-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-54-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,3-dihydro-3-hydroxy-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-55-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-5-yloxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-56-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(2-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-57-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[4-(2-propen-1-yl)-1H-indol-5-yl]oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-58-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-6-yloxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-60-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(6-benzoxazolyloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-61-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(1,2-benzisoxazol-6-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-62-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-63-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(3,7-dimethyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-64-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 724466-97-1P 724466-98-2P 724466-99-3P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation, PPAR α/γ/δ agonistic activity and SAR of (arylpropyloxy)indanylacetic acids starting from methoxyindanone using Reformatsky reaction, lipase-mediated kinetic resolution, etherification and cyclization as key steps)

RN 724466-97-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyanophenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-98-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-propylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-99-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-methoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 724466-72-2P 724466-75-5P 724466-80-2P
724466-83-5P 724466-84-6P 724466-87-9P
724466-88-0P 724466-89-1P 724466-93-7P
724466-94-8P 724466-96-0P 724467-00-9P
724467-01-0P 724467-02-1P 724467-03-2P
724467-05-4P 724467-06-5P 724467-07-6P
724467-08-7P 724467-10-1P 724467-13-4P
724467-16-7P 724467-18-9P 724467-19-0P
724467-20-3P 724467-21-4P 724467-22-5P
724467-28-1P 724467-32-7P 724467-34-9P
724467-36-1P 724467-38-3P 724467-42-9P
724467-48-5P 724467-52-1P 724467-53-2P
724467-54-3P 724467-57-6P 724467-60-1P
724467-61-2P 724467-64-5P 724467-65-6P
724467-66-7P 724467-67-8P 724467-68-9P
724467-69-0P 724467-70-3P 724467-76-9P
724467-78-1P 724467-79-2P 724467-80-5P
724467-81-6P 724467-82-7P 724467-83-8P
724467-87-2P 724467-88-3P 724467-89-4P
724467-93-0P 724467-94-1P 724467-95-2P
724467-96-3P 724468-00-2P 724468-01-3P
724468-06-8P 724471-07-2P 724471-08-3P
931115-47-8P 931115-56-9P 931115-58-1P
931115-59-2P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stereoselective preparation, PPAR α/γ/δ agonistic activity and SAR of (arylpropyloxy)indanylacetic acids starting from methoxyindanone using Reformatsky reaction, lipase-mediated kinetic resolution, etherification and cyclization as key steps)

RN 724466-72-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-75-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-80-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(6-methyl-2-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-83-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(3-phenoxypropoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-84-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-87-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(2,4-dimethylphenoxy)propoxy]-2,3-dihydro-,

(1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-88-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(2-methoxy-4-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-89-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(2-ethoxy-4-methylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-93-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-94-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethyl-2-methoxyphenoxy)propoxy]-2,3-

dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-96-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(trifluoromethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-00-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-01-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-phenoxy-2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-02-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-03-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(trifluoromethoxy)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-05-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1H-1,2,4-triazol-1-yl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-06-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[2-(acetylamino)-4-(1H-1,2,3-triazol-1-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-07-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[2-chloro-4-(4H-1,2,4-triazol-4-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-08-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-10-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(3-furanyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-13-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-([1,1'-biphenyl]-4-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-16-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-18-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4-methoxy-3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-19-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[5-(trifluoromethyl)-2-pyridinyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-20-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(5-pyrimidinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-21-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-22-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1H-indol-6-yl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-28-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-32-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-34-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-36-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-38-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-42-9 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-

inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-48-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-52-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-53-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methyl-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-54-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-57-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-60-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-61-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-64-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4,5-dimethyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-65-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4,5-dimethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-66-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-67-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-2-

propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-68-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-69-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-70-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-76-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-78-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4-methoxy-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-79-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methoxy-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-80-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-81-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-82-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-83-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[4-(1-methylethoxy)-2-thiazolyl]-2-propylphenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-87-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-88-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-89-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-93-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-[(dimethylamino)carbonyl]-4-methyl-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-94-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-[(dimethylamino)carbonyl]-4-methyl-2-thiazolyl]-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-95-2 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]phenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-96-3 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-00-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-01-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3-methoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-06-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(3,4-dimethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-07-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-08-3 ZCAPLUS
CN 4-Thiazoleacetic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 931115-47-8 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]-4-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 931115-56-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[5-methyl-4-(1-methylethoxy)-2-thiazolyl]-2-propylphenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 931115-58-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[5-methyl-4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 931115-59-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-ethyl-4-(1-methylethoxy)-2-thiazolyl]-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 724466-71-1P 724466-73-3P 724466-74-4P
724466-79-9P 724467-24-7P 724467-26-9P
724467-27-0P 724467-35-0P 724467-37-2P
724467-43-0P 931115-62-7P
RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation, PPAR α/γ/δ agonistic activity and SAR of (arylpropyloxy)indanylacetic acids starting from methoxyindanone using Reformatsky reaction, lipase-mediated kinetic resolution, etherification and cyclization as key steps)
RN 724466-71-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-73-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-iodophenoxy)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-74-4 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-thienyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-79-9 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(6-methyl-2-pyridinyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-24-7 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-26-9 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-27-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-35-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-37-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-43-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 931115-62-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)phenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 4 OF 29 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2004:565052 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:123483
TITLE: Preparation of indaneacetic acid derivatives and their use as pharmaceutical agents
INVENTOR(S): Cantin, Louis-David; Choi, Soongyu; Clark, Roger B.; Hentemann, Martin F.; Ma, Xin; Rudolph, Joachim; Liang, Sidney X.; Akuche, Christiana; Lavoie, Rico C.; Chen, Libing; Majumdar, Dyuti; Wickens, Philip L.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058174	A2	20040715	WO 2003-US40842	20031219
WO 2004058174	A3	20041202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2510793	A1	20040715	CA 2003-2510793		20031219
AU 2003299790	A1	20040722	AU 2003-299790		20031219
EP 1578715	A2	20050928	EP 2003-800063		20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006516251	T	20060629	JP 2004-563903		20031219
US 20060084680	A1	20060420	US 2005-537630		20050603
PRIORITY APPLN. INFO.:			US 2002-435310P	P	20021220
			WO 2003-US40842	W	20031219

OTHER SOURCE(S): MARPAT 141:123483

GI



I



II

AB The title compds. [I; R1, R2 = H, alkyl, cycloalkyl; L = (CH2)mX, Y(CH2)nX, etc.; X = O, S, SO, SO2, Y = O, S, SO, SO2, (un)substituted NH; m = 1-3; n = 2-4; Ar = (un)substituted Ph, 5-6 membered heteroaryl containing up to there N atoms] which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, coupling Et {(1S)-5-[3-(4-bromo-2- methoxyphenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl}acetate (preparation given) with 3-thiopheneboronic acid in the presence of PdCl2(dppf).CH2Cl2, NaHCO3 in DME/H2O followed by treatment of the resulting ester with LiOH afforded (1S)-II.

IT 724466-23-3P 724466-34-6P 724466-36-8P
724466-39-1P 724466-43-7P 724466-46-0P
724466-49-3P 724466-53-9P 724466-68-6P
724466-71-1P 724466-74-4P 724466-77-7P
724466-79-9P 724466-81-3P 724467-23-6P
724467-24-7P 724467-25-8P 724467-26-9P
724467-27-0P 724467-29-2P 724467-31-6P
724467-33-8P 724467-35-0P 724467-37-2P
724467-39-4P 724467-41-8P 724467-43-0P
724467-50-9P 724467-98-5P 724468-16-0P
724471-02-7P 724478-25-5P 724478-28-8P
724478-29-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724466-23-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-34-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-36-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-methyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-39-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-propyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-43-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-4-propyl-1H-indol-5-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-46-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-49-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-53-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,3-dihydro-3-hydroxy-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-68-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, ethyl ester (CA INDEX NAME)



RN 724466-71-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-74-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-thienyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-77-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(3-

thienyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-79-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(6-methyl-2-pyridinyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-81-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(phenylamino)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-23-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-propylphenoxy)propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-24-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-25-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-methoxyphenoxy)propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-26-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(aminothioxomethyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-27-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-29-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-31-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-33-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-35-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-37-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-39-4 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(2-ethoxy-2-oxoethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-(hydroxymethyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-41-8 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(2-ethoxy-2-oxoethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-43-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-50-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-98-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxy-2-propylphenoxy)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-16-0 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, methyl ester, (αR,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 724471-02-7 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[[3-[4-(6,7-dihydro-5H-pyrano[3,2-d]thiazol-2-yl)-2-propylphenoxy]propyl]thio]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724478-25-5 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724478-28-8 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-hydroxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724478-29-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 724466-17-5P 724466-24-4P 724466-25-5P
724466-26-6P 724466-27-7P 724466-28-8P
724466-29-9P 724466-30-2P 724466-31-3P
724466-32-4P 724466-35-7P 724466-37-9P
724466-40-4P 724466-44-8P 724466-47-1P
724466-50-6P 724466-54-0P 724466-55-1P
724466-56-2P 724466-57-3P 724466-58-4P
724466-59-5P 724466-60-8P 724466-61-9P
724466-62-0P 724466-63-1P 724466-64-2P
724466-65-3P 724466-66-4P 724466-69-7P
724466-72-2P 724466-75-5P 724466-78-8P
724466-80-2P 724466-82-4P 724466-83-5P
724466-84-6P 724466-86-8P 724466-87-9P
724466-88-0P 724466-89-1P 724466-90-4P
724466-91-5P 724466-92-6P 724466-93-7P
724466-94-8P 724466-95-9P 724466-96-0P
724466-97-1P 724466-98-2P 724466-99-3P
724467-00-9P 724467-01-0P 724467-02-1P
724467-03-2P 724467-04-3P 724467-05-4P
724467-06-5P 724467-07-6P 724467-08-7P
724467-09-8P 724467-10-1P 724467-11-2P
724467-12-3P 724467-13-4P 724467-14-5P
724467-15-6P 724467-16-7P 724467-17-8P
724467-18-9P 724467-19-0P 724467-20-3P
724467-21-4P 724467-22-5P 724467-28-1P
724467-30-5P 724467-32-7P 724467-34-9P
724467-36-1P 724467-38-3P 724467-40-7P
724467-42-9P 724467-48-5P 724467-51-0P
724467-52-1P 724467-53-2P 724467-54-3P
724467-55-4P 724467-56-5P 724467-57-6P
724467-58-7P 724467-59-8P 724467-60-1P

724467-61-2P 724467-62-3P 724467-63-4P
724467-64-5P 724467-65-6P 724467-66-7P
724467-67-8P 724467-68-9P 724467-69-0P
724467-70-3P 724467-71-4P 724467-72-5P
724467-73-6P 724467-74-7P 724467-75-8P
724467-76-9P 724467-77-0P 724467-78-1P
724467-79-2P 724467-80-5P 724467-81-6P
724467-82-7P 724467-83-8P 724467-84-9P
724467-85-0P 724467-86-1P 724467-87-2P
724467-88-3P 724467-89-4P 724467-90-7P
724467-91-8P 724467-92-9P 724467-93-0P
724467-94-1P 724467-95-2P 724467-96-3P
724467-97-4P 724467-99-6P 724468-00-2P
724468-01-3P 724468-02-4P 724468-04-6P
724468-05-7P 724468-06-8P 724468-07-9P
724468-09-1P 724468-10-4P 724468-11-5P
724468-12-6P 724468-13-7P 724468-14-8P
724468-15-9P 724468-17-1P 724468-18-2P
724471-03-8P 724471-07-2P 724471-08-3P
724471-09-4P 724471-10-7P 724471-11-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724466-17-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-24-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-25-5 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(1H-indol-5-yloxy)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-26-6 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(2-methyl-1H-indol-5-yl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-27-7 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(1H-indol-6-yloxy)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-28-8 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(1H-indol-4-yloxy)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-29-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(3-methyl-6-benzofuranyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-30-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[(2-methyl-5-benzothiazolyl)oxy]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-31-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(6-quinolinyloxy)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-32-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(7-quinolinyloxy)ethoxy]-, (1S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 724466-35-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-1H-indol-5-
yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-37-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-methyl-1H-indol-5-
yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-40-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(4-propyl-1H-indol-5-
yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-44-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(1-methyl-4-propyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-47-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-50-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-54-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,3-dihydro-3-hydroxy-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-55-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-5-yloxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-56-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(2-methyl-1H-indol-5-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-57-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[4-(2-propen-1-yl)-1H-indol-5-yl]oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-58-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-6-yloxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-59-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(1H-indol-4-yloxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-60-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(6-benzoxazolyloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-61-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(1,2-benzisoxazol-6-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-62-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(3-methyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-63-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(3,7-dimethyl-1,2-benzisoxazol-6-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-64-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-65-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(5,6,7,8-tetrahydro-1-naphthalenyl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-66-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)oxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-69-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]- (CA INDEX NAME)



RN 724466-72-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-75-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-78-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(3-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-80-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(6-methyl-2-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-82-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(phenylamino)propoxy]-, (1S)-

(CA INDEX NAME)

Absolute stereochemistry.



RN 724466-83-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-(3-phenoxypropoxy)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-84-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-86-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-87-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(2,4-dimethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-88-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(2-methoxy-4-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-89-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(2-ethoxy-4-methylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-90-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(2-bromo-4-methylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-91-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-methyl-2-[(1-oxobutyl)amino]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-92-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-(5-isoxazolyl)-4-methylphenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-93-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-94-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethyl-2-methoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-95-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1-methylethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-96-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(trifluoromethyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-97-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyanophenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-98-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-propylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-99-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-cyano-2-methoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-00-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-01-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-phenoxy-2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-02-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-03-2 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(trifluoromethoxy)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-04-3 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-05-4 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1H-1,2,4-triazol-1-yl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-06-5 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[2-(acetylamino)-4-(1H-1,2,3-triazol-1-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-07-6 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[2-chloro-4-(4H-1,2,4-triazol-4-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-08-7 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-09-8 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[4,5-dihydro-4-hydroxy-4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-10-1 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(3-furanyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-11-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-12-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methyl-2-thienyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-13-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-([1,1'-biphenyl]-4-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-14-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(3,4'-dimethoxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-15-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(4'-fluoro-3-methoxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-16-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-17-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(3-pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-18-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4-methoxy-3-

pyridinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-19-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[5-(trifluoromethyl)-2-pyridinyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-20-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(5-pyrimidinyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-21-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-22-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(1H-indol-6-yl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-28-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-30-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-32-7 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-34-9 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-36-1 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(1-methylethoxy)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-38-3 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-40-7 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-42-9 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-methoxyphenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-48-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(2-benzothiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-51-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-52-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-53-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methyl-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-54-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-55-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-56-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-57-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-58-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-oxazolyl]phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-59-8 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[3-[4-[4-(1,1-dimethylethyl)-2-oxazolyl]-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-60-1 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-61-2 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(trifluoromethyl)-2-thiazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-62-3 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[4-(trifluoromethyl)-2-oxazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-63-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-[4-(trifluoromethyl)-2-oxazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-64-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4,5-dimethyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-65-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4,5-dimethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-66-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-67-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-68-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-69-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-70-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-71-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-72-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-73-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[2-ethoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-74-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propoxy-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-75-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4,5,6,7-tetrahydro-2-benzoxazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-76-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-77-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-5,5-dimethyl-7-oxo-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-78-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-(4-methoxy-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-79-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-methoxy-4-(4-methoxy-2-thiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-80-5 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-81-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-82-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-83-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[4-(1-methylethoxy)-2-thiazolyl]-2-propylphenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-84-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-5-methyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-85-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-5-methyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-86-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(4-ethoxy-5-ethyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-87-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-88-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-89-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-thiazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-90-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-oxazolyl)phenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-91-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-oxazolyl)-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-92-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(5-acetyl-4-methyl-2-oxazolyl)-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-93-0 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-[(dimethylamino)carbonyl]-4-methyl-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-94-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-[(dimethylamino)carbonyl]-4-methyl-2-thiazolyl]-2-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-95-2 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]phenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-96-3 ZCAPLUS
CN 5-Thiazolecarboxylic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-97-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[4-[5-hydroxy-4-(trifluoromethyl)-2-oxazolyl]phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724467-99-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-methoxy-2-propylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-00-2 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3-methylphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-01-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3-methoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-02-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-([1,1'-biphenyl]-3-yloxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-04-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(2,3-dimethoxyphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-05-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(acetylamino)-3-methoxyphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-06-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(3,4-dimethylphenoxy)propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-07-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(3,4,5-trimethoxyphenoxy)propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-09-1 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, methyl ester, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-10-4 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[2-methyl-4-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy]propoxy]-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-11-5 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-12-6 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[(3-methyl-6-benzofuranyl)oxy]propoxy]-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-13-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[4-(trifluoromethyl)phenoxy]propoxy]-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-14-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-ethylphenoxy)propoxy]-2,3-dihydro-α-methyl-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-15-9 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy]-, (αS,1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-17-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[[7-propyl-3-

(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (αR,1R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 724468-18-2 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-α-methyl-5-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propoxy]-, (αR,1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-03-8 ZCAPLUS

CN 1H-Indene-1-acetic acid, 5-[[3-[4-(6,7-dihydro-5H-pyrano[3,2-d]thiazol-2-yl)-2-propylphenoxy]propyl]thio]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-07-2 ZCAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[2-propyl-4-(4,5,6,7-tetrahydro-2-benzothiazolyl)phenoxy]propoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-08-3 ZCAPLUS
CN 4-Thiazoleacetic acid, 2-[4-[3-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]propoxy]-3-propylphenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-09-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-[5-(dimethylamino)-4-methyl-2-thiazolyl]-2-propylphenoxy]propoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-10-7 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propoxyphenoxy]propoxy]-2,3-dihydro-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724471-11-8 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[[3-[4-(6,7-dihydro-5H-pyrano[2,3-d]thiazol-2-yl)-2-propoxyphenoxy]propyl]thio]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 724466-73-3P 724466-76-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)
RN 724466-73-3 ZCAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-(4-iodophenoxy)propoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 724466-76-6 ZCAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



L67 ANSWER 5 OF 29 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:529163 ZCAPLUS Full-text
DOCUMENT NUMBER: 123:44332
ORIGINAL REFERENCE NO.: 123:7815a,7818a
TITLE: High-sensitivity positively charging electrophotographic photoreceptor

INVENTOR(S): Ooshiba, Tomomi; Hirose, Hisahiro; Hai, Genko; Fujimoto, Shingo
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07056369	A	19950303	JP 1993-199586	19930811

PRIORITY APPLN. INFO.: JP 1993-199586 19930811
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The photoreceptor has an elec. conductive support coated with a photosensitive layer containing (heterocyclic) aromatic compound I, II, III, or IV [Q, Q1-3 = O, C(CN)2, CHCN, CY2, C(CO2R)2, CHCO2R, CHR, NR, HCN; Y = halo; R = H, alkyl, Ph, heterocyclic group; X = O, CO, NH, (substituted) aliphatic group, aromatic hydrocarbyl; R, R1-3 = (substituted) alkyl, aryl, alkoxy, acyl, ester, cyano, NO2, amide, sulfone, sulfonamide, OH, CHO, halo; A1-2, B1-2 = (substituted) aromatic hydrocarbyl, heterocyclic group; l, m, j, k ≥0] as charge-transporting agents. The photoreceptor showed low residual potential and gave clear images.

IT 163967-44-0
RL: DEV (Device component use); USES (Uses)
(electrophotog. photoreceptor containing (heterocyclic) aromatic compound charge-transporting agent with high sensitivity)

RN 163967-44-0 ZCAPLUS
CN Acetic acid, 2,2'-[carbonylbis[oxy[6-ethoxy-2,7-bis(trifluoromethyl)-9H-fluoren-4-yl-9-ylidene]]]bis-, diethyl ester (9CI) (CA INDEX NAME)



L67 ANSWER 6 OF 29 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:18158 ZCAPLUS Full-text
DOCUMENT NUMBER: 106:18158
ORIGINAL REFERENCE NO.: 106:3105a,3108a
TITLE: Indanylacetic acid derivatives
INVENTOR(S): Murase, Kiyoshi; Hara, Hiroshi; Mase, Toshiyasu; Tomioka, Kenichi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61097241	A	19860515	JP 1984-217843	19841016

PRIORITY APPLN. INFO.: JP 1984-217843 19841016
OTHER SOURCE(S): CASREACT 106:18158
GI For diagram(s), see printed CA Issue.
AB Title compds. I [R = alkyl, alkanoyl; R1 = alkyl; R2 = R3 = H, or R2 = H and R3 = OH, lower alkoxy; R2R3 = oxo; R4 = H, alkyl; Z = (OH-substituted) alkylene; n = 1, 2, 3; A = 5-6 membered ring; R3R4 may form lactone when R3 = OH and R4 = H], useful as antiallergic agents because of their inhibiting activities against slow reacting substance of anaphylaxis (no data), were prepared Thus, 1.48 g (bromopropoxy)indanylacetate II was treated with 1.18 g 2,4-dihydroxy-3-propylacetophenone in DMF over K2CO3 at 45° to give 930 mg (phenoxypropoxy)indanylacetate derivative III.
IT 105806-39-1P 105806-40-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiallergic agent)
RN 105806-39-1 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2,3-dihydro-, ethyl ester (CA INDEX NAME)



RN 105806-40-4 ZCAPLUS
CN 1H-Indene-1-acetic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2,3-dihydro- (CA INDEX NAME)



L67 ANSWER 7 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
(ALL HITs ARE ITERATION INCOMPLETES)
ACCESSION NUMBER: 148:537935 MARPAT Full-text
TITLE: Preparation of anthraquinone derivatives as anti-inflammatory agents
INVENTOR(S): Walmsley, Andrea
PATENT ASSIGNEE(S): Sosei R & D Ltd., UK
SOURCE: PCT Int. Appl., 14pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008056156	A1	20080515	WO 2007-GB4280	20071109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-22479 20061110
GI



I

AB The title compds. with general formula I•Y [wherein X1 and X2 = independently H or an ester group, with the proviso that X1 and X2 can not both be H; Y = amine] or hydrates thereof were prepared for use in pharmaceutical compns. useful in the treatment of inflammatory or autoimmune diseases or conditions associated with T-cell proliferation or that are mediated by pro-inflammatory cytokines. These autoimmune and inflammatory diseases and conditions may include chronic degenerative disease, such as rheumatoid arthritis, osteoarthritis or osteoporosis, chronic demyelinating disease, such as multiple sclerosis, respiratory disease, such as asthma or chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) such as ulcerative colitis or Crohn's disease, dermatol. conditions, such as psoriasis, scleroderma or atopic dermatitis, dental diseases, such as periodontal disease or gingivitis, diabetic nephropathy, lupus nephritis, IgA nephropathy, glomerulonephritis, systemic lupus erythematosus (SLE), graft vs. host disease. For example, 4a,9,9a,10-tetrahydro-9,10-dioxo-4,5-bis[2-oxo-2-(tetrahydro-2H-pyran-4-yl)ethyl]-2-anthracenecarboxylic acid and 4-(2-hydroxyethyl)morpholine were stirred for 1 day in THF from 10-60 ℃, and the reaction mixture was concentrated under dry N2 flow to a suspension of small volume before been filtered and dried under vacuum at room temperature to give the 4-(2-hydroxyethyl)morpholine salt of the previous compound as a final product.

MSTR 1 ITERATION INCOMPLETE



G13

G1 = OH / 20

G2 = OH / 22



G3 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G4) /
heterocycle <containing 4-7 atoms, 1 or more heteroatoms,
zero or more N, zero or more O,
zero or more S (no other heteroatoms), monocyclic>
(opt. substd. by 1 or more G7) / 100 / 102 /
(Specifically claimed: 142 / 143 / 150)



G4 = F / CF3 / OH / NH2 / 26 /
heterocycle <containing 4-6 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, non-aromatic,
saturated, monocyclic> (opt. substd. by 1 or more G7) / 30 /
32 / 35



G5 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G20)
G6 = heterocycle <containing 4-6 atoms,
1 or more heteroatoms, 1 or more N, zero or more O,
zero or more S (no other heteroatoms),
attached through 1 or more N, non-aromatic, saturated,
monocyclic> (opt. substd.)
G7 = F / CF3 / OH / NH2 / 39 /
heterocycle <containing 4-6 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, non-aromatic,
saturated, monocyclic> (opt. substd.) / 41 / 43 / 46 /
alkyl <containing 1-4 C> (opt. substd. by 1 or more G12)



G8 = S / S(O) / SO2
G9 = alkyl <containing 1-4 C>
G10 = NH / 28 / O



G11 = heterocycle <containing 4-6 atoms,
1 or more heteroatoms, 1 or more N, zero or more O,
zero or more S (no other heteroatoms),
attached through 1 or more N, non-aromatic, saturated,
monocyclic> (opt. substd.)
G12 = F / CF3 / OH / NH2 / 50 /
heterocycle <containing 4-6 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, non-aromatic,
saturated, monocyclic> (opt. substd.) / 52 / 54 / 57 / Cl /
Br / I



G13 = NH3 / 60 / 62 / heterocycle <containing 4-7 atoms,
1 or more heteroatoms, 1 or more N, zero or more O,
zero or more S (no other heteroatoms), monocyclic>
(opt. substd. by 1 or more G18) / 95 / 97 /
(Specifically claimed: 122 / 134)





G14 = alkyl <containing 1-4 C>
G15 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G16)
G16 = F / CF3 / OH / NH2 / 66 /
heterocycle <containing 4-6 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, non-aromatic,
saturated, monocyclic> (opt. substd. by 1 or more G7) / 68 /
70 / 73 / Cl / Br / I



G17 = NH2 / 75 / 77 / 79



G18 = F / CF3 / OH / NH2 / 84 /
heterocycle <containing 4-6 atoms, 1 or more heteroatoms, 1 or more N, zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, non-aromatic, saturated, monocyclic> (opt. substd.) / 86 / 88 / 91 /
alkyl <containing 1-4 C> (opt. substd. by 1 or more G12) /
93



G19 = heterocycle <containing 4-7 atoms,
1 or more heteroatoms, 1 or more N, zero or more O,
zero or more S (no other heteroatoms), monocyclic>
(opt. substd.)
G20 = F / CF3 / OH / NH2 / 107 /
heterocycle <containing 4-7 atoms, 1 or more N,
zero or more O, zero or more S (no other heteroatoms),
attached through 1 or more N, non-aromatic, saturated,
monocyclic> (opt. substd.) / 109 / 111 / 114



G21 = alkyl <containing 1-4 C> (opt. substd.)
G22 = NH / 116 / O



Patent location: claim 1
Note: and hydrates
Note: substitution is restricted

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 8 OF 29 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 147:385839 MARPAT Full-text
TITLE: Preparation of coumarin and related carbocycle and heterocyclic analogs useful for treating metabolic disorders
INVENTOR(S): Sharma, Rajiv; Akerman, Michelle; Cardozo, Mario G.; Houze, Jonathan B.; Li, An-Rong; Liu, Jinqian; Liu, Jiwen; Ma, Zhihua; Medina, Julio C.; Schmitt, Michael J.; Sun, Ying; Wang, Yingcai; Wang, Zhongyu; Zhu, Liusheng
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 194pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007106469	A2	20070920	WO 2007-US6279	20070312
WO 2007106469	A3	20071221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20070244155	A1	20071018	US 2007-717945	20070313
PRIORITY APPLN. INFO.:			US 2006-782706P	20060314
			US 2007-905207P	20070305

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = aryl or heterocyclic group; B = 5-7 membered carbocycle or heterocycle; R1 = halo, CN, alkyl, etc.; R2 = halo, OH, alkoxy, etc.; n = 0-2; p = 0-2; q = 0-2 ;X = CRaRb wherein Ra and Rb independently = H or halo; wherein each alkyl, aryl, and heterocycle or carbocycle in I is optionally substituted], and their pharmaceutically acceptable salts, are prepared and disclosed for treating metabolic disorders. Thus, e.g., II was prepared in a multistep synthesis starting from 6-hydroxy-1-tetralone. I were evaluated in insulin secretion assays, e.g, II demonstrated an EC50 value of < 1 μM and greater or equal to 0.1 μM. Compns. and methods for using the compds. for preparing medicaments and for treating metabolic disorders such as, for instance, type II diabetes are disclosed.

MSTR 1



G1 = (0-2) 5

G3 = 88-1 86-3



G11 = 298



G23 = bond
G29 = 303-2 305-299



G30 = O
G31 = (1-2) CH2
G32 = phenylene (opt. substd. by 1 or more G38)
Patent location: claim 1
Note: or pharmaceutically acceptable salts, esters, solvates, tautomers or prodrugs
Note: also incorporates claims 11, 23, 34 and 42
Note: substitution is restricted
Note: additional heteroatom interruptions and substitution also claimed
Stereochemistry: or stereoisomers

L67 ANSWER 9 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 147:269260 MARPAT Full-text
TITLE: Heterocyclic modulators of PPAR
INVENTOR(S): Bennett, Dennis A.; Severance, Daniel L.; Semple, J. Edward
PATENT ASSIGNEE(S): Kalypsys, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 74pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070191371	A1	20070816	US 2007-675067	20070214
PRIORITY APPLN. INFO.:			US 2006-773289P	20060214

AB The present invention relates to compds. and methods useful as modulators of Peroxisome Proliferator-Activated Receptors (PPARs) for treatment or prevention of disease.

MSTR 1



G1 = 103



G2 = 4-1 6-3



G3 = Ph (opt. substd. by 1 or more G10)
G4 = S
G5 = (1-4) CH2
G21 = 2

Patent location: claim 1
Note: or salts, esters, or prodrugs

L67 ANSWER 10 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 148:262617 MARPAT Full-text
TITLE: Preparation of pyrimidine- and triazine-derivative endothelin receptor antagonists

INVENTOR(S): Riechers, Hartmut; Klinge, Dagmar; Amberg, Wilhelm; Kling, Andreas; Mueller, Stefan; Baumann, Ernst; Rheinheimer, Joachim; Vogelbacher, Uwe Josef; Wernet, Wolfgang; Unger, Liliane; Raschack, Manfred
PATENT ASSIGNEE(S): Abbott Gmbh & Co. KG, Germany
SOURCE: U.S., 18pp., Cont. of U.S. Ser. No. 748,184.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7109205	B2	20060919	US 2003-602275	20030624
US 20040092742	A1	20040513		
DE 19533023	A1	19960418	DE 1995-19533023	19950907
DE 19533023	B4	20070516		
WO 9611914	A1	19960425	WO 1995-EP3963	19951007
W: AU, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1110952	A1	20010627	EP 2001-103889	19951007
EP 1110952	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 5932730	A	19990803	US 1997-809699	19970327
US 5969134	A	19991019	US 1998-184152	19981102
US 6197958	B1	20010306	US 1999-309770	19990511
US 20020052495	A1	20020502	US 2000-748184	20001227
US 6600043	B2	20030729		
US 20060160808	A1	20060720	US 2006-377879	20060316
US 7119097	B2	20061010		
US 20060276645	A1	20061207	US 2006-502257	20060810
US 20060276474	A1	20061207	US 2006-502293	20060810
US 20070203338	A1	20070830	US 2007-789630	20070425

PRIORITY APPLN. INFO.:
DE 1994-4436851 19941014
DE 1995-19533023 19950907
WO 1995-EP3963 19951007
US 1997-809699 19970327
US 1998-184152 19981102
US 1999-309770 19990511
US 2000-748184 20001227
EP 1995-935916 19951007
US 2003-602275 20030624
US 2006-502257 20060810

GI



I



II

AB The title compds. I [R = CHO, tetrazolyl, CN, CO2H, groups cleavable to CO2H; R2 = (un)substituted NH2, halogen, (un)substituted alkyl, etc.; R3 = H, OH, (un)substituted NH2, halogen, (un)substituted alkyl, etc.; R4, R5 = (un)substituted Ph or naphthyl; R6 = H, alkyl, alkenyl, alkynyl, alkylcarbonyl, (un)substituted Ph, etc.; X = N, (un)substituted CH; Y = direct bond, S, O; Z = S, O, SO, SO2, direct bond], and their pharmaceutically acceptable salts, are prepared and disclosed as endothelin receptor antagonists. In receptor binding assays, pyrimidine derivative II (R2 and R3 = MeO), m.p. 167°, demonstrated a Ki ETA of 6 nM. In particular, the racemate and individual enantiomers of II (R2 and R3 = Me) are claimed.

MSTR 1B



G1 = CO2H
G12 = 52



G15 = bond
G26 = carbon chain <containing 1-8 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by G27)
G27 = OPh (substd. by 1 or more G28)
G33 = bond
G34 = S
Patent location: disclosure
Note: substitution is restricted

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 11 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 142:420119 MARPAT Full-text
TITLE: Chromene compound and photochromic material containing it
INVENTOR(S): Momota, Junji; Kawabata, Yuichiro; Tanaka, Nobuyuki; Iwata, Arihiro
PATENT ASSIGNEE(S): Tokuyama Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005112772	A	20050428	JP 2003-348365	20031007

PRIORITY APPLN. INFO.: JP 2003-348365 20031007

GI



I

AB A chromene compound I having indeno(2,1-f)naphtho(1,2-b)pyran structure having a substituent with absolute Hammett σp value ≥0.01 at 8-position. Photochromic composition contains I. A photochromic material comprising the chromene compound-dispersed polymer mold or an optical material coated with the chromene compound-dispersed polymer are also claimed. I shows rapid coloring and decoloring response, gives clear middle tone color, and is useful for photochromic glasses.

MSTR 1



G1 = 32



G4 = CO2H
G5 = 22 / 31



G12 = OPh (opt. substd. by (1-2) alkyl <containing 1-6 C>
)
Patent location: claim 2
Note: additional ring formation also claimed

L67 ANSWER 12 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:8129 MARPAT Full-text
TITLE: Photochromic naphthopyran compounds and compositions and articles containing them
INVENTOR(S): Qin, Xuzhi
PATENT ASSIGNEE(S): Vision-Ease Lens, Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003044022	A2	20030530	WO 2002-US37469	20021120
WO 2003044022	A3	20040122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 20030146419	A1	20030807	US 2001-38350	20011120
US 7008568	B2	20060307		
AU 2002357749	A1	20030610	AU 2002-357749	20021120
EP 1446406	A2	20040818	EP 2002-792287	20021120
EP 1446406	B1	20060329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-38350 20011120
WO 2002-US37469 20021120

GI

F 

AB Photochromic naphthopyrans (I; R1, R2 = atoms or groups providing photochromic properties; ring A = 5-, 6-, or 7-membered heterocyclic ring having only one O, S, or N heteroatom) displaying good color distribution are disclosed. In an example, 3-(4-methoxyphenyl)-3,13-diphenyl-13- hydroxy-3H-(4,5-dihydrofurano[2,3-b]indeno[3,2-f]naphtho)[1,2-b]pyran was prepared from 2,3-dihydrobenzofuran, benzoyl chloride, di-Me succinate, 1-(4-methoxyphenyl)-1-phenyl-2-propyn-1-ol, and PhMgBr.

MSTR 1



G4 = 75



G5 = 209 / 227

G15 = 212



G16 = NH
G17 = Ph
G29 = 229



G30 = OH
Patent location: claim 1
Note: additional derivatization also claimed

L67 ANSWER 13 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:47350 MARPAT Full-text
TITLE: Preparation of fused dihydroindole derivatives as agents useful for reducing amyloid precursor protein and treating dementia
INVENTOR(S): Greig, Nigel H.; Shaw, Karen T. Y.; Yu, Qiang-Sheng; Holloway, Harold W.; Utsuki, Tada; Soncrant, Timothy T.; Ingram, Donald S.; Brossi, Arnold; Giordano, Anthony; Powers, Gordon; Davidson, Diane; Sturgess, Michael
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048150	A2	20020620	WO 2001-US48175	20011102
WO 2002048150	A3	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465534	A1	20020620	CA 2001-2465534	20011102
AU 2002043323	A	20020624	AU 2002-43323	20011102
EP 1349858	A2	20031008	EP 2001-989211	20011102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2002243323	B2	20070712	AU 2002-243323	20011102
US 20040138282	A1	20040715	US 2004-415765	20040206
US 7153882	B2	20061226		
US 20060270729	A1	20061130	US 2006-455959	20060620
PRIORITY APPLN. INFO.:			US 2000-245329P	20001102
			WO 2001-US48175	20011102
			US 2004-415765	20040206

GI



I



II



III

AB The present invention provides title compds. I and II [R1, R2 = independently H, (un)branched C1-8 alkyl, (un)substituted aryl, aralkyl; R3 = (un)branched C1-4 alkyl, heteroalkyl, C4-8 alkyl, heteroalkyl; (un)substituted aryl; X, Y = independently O, S, alkyl, hydrocarbyl, CHR4, NR5; R4, R5 = independently H, O, (un)branched C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, aralkyl, (un)substituted aryl; R6 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aralkyl, (un)substituted aryl, (CH2)nR7; R7 = OH, alkoxy, CN, ester, CO2H, (un)substituted amino; n = 1-4], with provisos, and methods of administering compds. to a subject that can reduce β-amyloid precursor protein (βAPP) production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compds. and methods of administering such compds. to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compds. can be used to decrease βAPP production Thus, benzylation of N,N-dimethyl-5-methoxytryptamine with benzyl bromide gave 30% non-carbamate inhibitor MES 9191 (III). III inhibited βAPP mRNA levels by about 10%, relative to control.

MSTR 1



G1 = 27



G2 = Ph (opt. substd.)
G8 = 38



G10 = 40



G11 = (1-4) CH2
G12 = 42



Patent location: claim 1
Note: substitution is restricted
Note: additional heteroatom interruptions in G7 also claimed
Note: also incorporates claim 73

L67 ANSWER 14 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 134:131546 MARPAT Full-text
TITLE: Preparation of pyrimidinyloxypropionates as endothelin receptor antagonists.
INVENTOR(S): Amberg, Wilhelm; Kettschau, Georg
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005771	A1	20010125	WO 2000-EP6293	20000705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19933164	A1	20010125	DE 1999-19933164	19990720
CA 2379545	A1	20010125	CA 2000-2379545	20000705
EP 1196394	A1	20020417	EP 2000-953009	20000705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000012592	A	20020528	BR 2000-12592	20000705
CN 1367778	A	20020904	CN 2000-810533	20000705
JP 2003505377	T	20030212	JP 2001-511432	20000705

HU 2002002646	A2	20030228	HU 2002-2646	20000705
HU 2002002646	A3	20030328		
TW 555749	B	20031001	TW 2000-89113992	20000713
ZA 2002000333	A	20030217	ZA 2002-333	20020115
NO 2002000254	A	20020220	NO 2002-254	20020117
MX 2002PA00616	A	20020830	MX 2002-PA616	20020117
BG 106321	A	20020830	BG 2002-106321	20020118
KR 2002019550	A	20020312	KR 2002-7000815	20020119
PRIORITY APPLN. INFO.:			DE 1999-19933164	19990720
			WO 2000-EP6293	20000705

GI



I

AB Title compds. [I; R = tetrazolyl, acyl; R2 = OH, amino, alkyl, alkenyl, alkynyl, hydroxyalkyl, alkylthio, etc.; R3 = OH, amino, halo, alkyl, alkenyl, alkynyl, alkenyloxy, haloalkyl, alkoxy, haloalkoxy, alkylthio, etc.; R2R3 = atoms to form a 5-6 membered ring; R4, R5 = (substituted) Ph, naphthyl, cycloalkyl; R6 = H, (substituted) alkyl, alkenyl, alkynyl, Ph, naphthyl, heteroaryl; Z = O, S], were prepared Thus, a suspension of NaH in DMF at 0° was treated with (S)-2-hydroxy-3-methoxy-3,3- diphenylpropionic acid in DMF and then with 2-methylsulfonyl-4-methoxy-5- methylpyrimidine (preparation given) in DMF followed by stirring overnight to give (S)-2-(4-methoxy-5-methylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylpropionic acid. The latter showed Ki = 0.6 nM for binding to ETA receptors.

MSTR 1



G1 = 9

G2 = OH
G14 = 72

$_{72}$G15—G16

G15 = O
G16 = alkyl <containing 1-8 C>
(opt. substd. by 1 or more G37)
G17 = 90



G19 = bond
G37 = OPh (opt. substd.)
Patent location: claim 1
Note: substitution is restricted
Note: and physiolocially acceptable salts
Stereochemistry: and enantiomerically pure or diastereomerically pure forms

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 15 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 133:247292 MARPAT Full-text
TITLE: Amyotropic lateral sclerosis treatment with a combination of riluzole and an AMPA receptor antagonist
INVENTOR(S): Bohme, Andrees; Boireau, Alain; Canton, Thierry; Pratt, Jeremy; Stutzmann, Jean-Marie
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000054772	A1	20000921	WO 2000-FR590	20000310
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2790670	A1	20000915	FR 1999-3100	19990312
EP 1161238	A1	20011212	EP 2000-910920	20000310

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002539162 T 20021119 JP 2000-604848 20000310

PRIORITY APPLN. INFO.: FR 1999-3100 19990312
US 1999-129318P 19990414
WO 2000-FR590 20000310

AB The invention discloses the prevention and/or treatment of amyotropic lateral sclerosis with a combination of riluzole and one or several AMPA receptor antagonists, as well as combinations of these compds. and pharmaceutical compns. containing them.

MSTR 4



G1 = 19



G3 = alkylene <containing 1-6 C>
G4 = OH
G7 = 39



Patent location: claim 7
Note: and pharmaceutically acceptable salts
Stereochemistry: and isomers, enantiomers and diastereoisomers

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 16 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 132:352526 MARPAT Full-text
TITLE: Novel indanylidene compounds as sunscreens
INVENTOR(S): Bringhen, Alain; Huber, Ulrich
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1000950	A2	20000517	EP 1999-122210	19991106
EP 1000950	A3	20020403		
EP 1000950	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2288854	A1	20000511	CA 1999-2288854	19991105
AT 260284	T	20040315	AT 1999-122210	19991106
ES 2213962	T3	20040901	ES 1999-122210	19991106
JP 2000143608	A	20000526	JP 1999-316259	19991108
JP 4084514	B2	20080430		
KR 2000035293	A	20000626	KR 1999-49173	19991108
IN 1999MA01075	A	20080307	IN 1999-MA1075	19991108
BR 9905353	A	20000919	BR 1999-5353	19991110
CN 1253943	A	20000524	CN 1999-123540	19991111
US 6416746	B1	20020709	US 1999-438199	19991111

PRIORITY APPLN. INFO.: EP 1998-121456 19981111

AB The invention relates to novel indanylidene compds. which are effective in absorbing UV radiation and to light screening compns. comprising said indanylidene compds. In addition to indanylidene compds. of the present invention, sunscreening compns. contain common UB-A and/or UV-B screening agents. For example, cyano-(2,3-dihydro-5,6-dimethoxy-3,3-dimethyl-1H- inden-1-ylidene) acetic acid-3-(pentamethyldisiloxanyl)-Pr ester (I) was prepared and an oil/water broad spectrum sunscreen lotion containing 2% I, 2% Parsol MCX, and 3% Parsol 1789 was formulated.

MSTR 1



G1 = O
G2 = 73



G11 = 1-2 5-4



G12 = CH2CH2CH2
G14 = 198



G15 = Ph
Patent location: claim 1
Note: substitution is restricted
Note: additional oxygen atom interruption(s) in G3 and G9 alkyl moieties also claimed

L67 ANSWER 17 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 134:29428 MARPAT Full-text
TITLE: Preparation of 2-pyrimidinyloxypropanoates and analogs as endothelin receptor antagonists
INVENTOR(S): Amberg, Wilhelm; Kettschau, Georg
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19924892	A1	20001207	DE 1999-19924892	19990601
CA 2375666	A1	20001207	CA 2000-2375666	20000519
WO 2000073276	A2	20001207	WO 2000-EP4571	20000519
WO 2000073276	A3	20010510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1181281	A2	20020227	EP 2000-938660	20000519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011105	A	20020305	BR 2000-11105	20000519

TR 200103475	T2	20020422	TR 2001-3475	20000519
HU 2002001387	A2	20020828	HU 2002-1387	20000519
HU 2002001387	A3	20041228		
JP 2003500476	T	20030107	JP 2000-621342	20000519
AU 765345	B2	20030918	AU 2000-53959	20000519
NO 2001005762	A	20011213	NO 2001-5762	20011126
BG 106154	A	20020830	BG 2001-106154	20011127
MX 2001PA12284	A	20020730	MX 2001-PA12284	20011129
PRIORITY APPLN. INFO.:			DE 1999-19924892	19990601
			WO 2000-EP4571	20000519

GI



II

AB R3Z3CR4R5CHR1OZ2R2 [I; R1 = tetrazolyl, CO2H, [(oxo)thia]alkoxycarbonyl, N-attached azolylcarbonyl, alkylsulfonylcarbamoyl, etc.; R2 = cycloalkyl, Ph, PhO, heteroaryl, etc.; R3 = H, alkyl, (hetero)aryl, etc.; R4,R5 = cycloalkyl, Ph, naphthyl, etc.; Z2 = N-containing heteroarylene; Z3 = O or S] were prepared Thus, 4-methyl-6-phenylpyrimidine-2-thiol was S-methylated and the oxidized product condensed with EtOCPh2CH(OH)CO2H to give title compound II. Data for biol. activity of I were given.

MSTR 1



G1 = 9

G2 = OH
G14 = 72



G15 = O
G16 = alkyl <containing 1-8 C>
(opt. substd. by 1 or more G37)
G17 = 90



G19 = bond
G37 = OPh (opt. substd.)
Patent location: claim 1
Note: substitution is restricted
Note: and physiolocially acceptable salts
Stereochemistry: and enantiomerically pure or diastereomerically pure forms

L67 ANSWER 18 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 133:309846 MARPAT Full-text
TITLE: Preparation of azinylaminopropoxydibenzoazulenes as integrin inhibitors.
INVENTOR(S): Staehle, Wolfgang; Gottschlich, Rudolf; Goodman, Simon
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19916837	A1	20001019	DE 1999-19916837	19990414
CA 2367359	A1	20001026	CA 2000-2367359	20000401
WO 2000063178	A1	20001026	WO 2000-EP2925	20000401
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000009690	A	20020108	BR 2000-9690	20000401
EP 1169306	A1	20020109	EP 2000-917037	20000401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2002000643	A2	20020729	HU 2002-643	20000401
HU 2002000643	A3	20031028		
JP 2002542231	T	20021210	JP 2000-612271	20000401

MX 2001PA10294	A	20020506	MX 2001-PA10294	20011011
NO 2001004976	A	20011012	NO 2001-4976	20011012
US 6521646	B1	20030218	US 2001-958812	20011015
ZA 2001009343	A	20030213	ZA 2001-9343	20011113
PRIORITY APPLN. INFO.:			DE 1999-19916837	19990414
			WO 2000-EP2925	20000401

GI



I

AB Title compds. [I; R1 = OR4, NHR4, NA2; R2 = H, halo, NO2, NHR4, NA2, OR4, SO2R4, SR4, etc.; R3 = NH2, H2N(C:NH), R5NH, etc.; R4 = H, alkyl, (substituted) aryl, aralkyl; R5 = (substituted) heterocyclyl; A = (substituted) (heteroatom-interrupted) alkyl; m, n = 0-4; dotted line = optional double bond], were prepared as integrin inhibitors (no data). Thus, Me 8-hydroxy-6,11-dihydro-2H-dibenzo[cd,g]azulen-1-carboxylate (preparation given) was stirred with Ph3P, di-Et azodicarboxylate, and 2-(3-hydroxypropylamino)pyridine N-oxide in DMG to give Me 8-[3-(1-oxypyridin-2-ylamino)propoxy]-6,11-dihydro-2H-dibenzo[cd,g]azulen- 1-carboxylate. The latter was refluxed with PCl3 in CHCl3 to give Me 8-[3-(pyridin-2-ylamino)propoxy]-6, 11-dihydro-2H-dibenzo[cd,g]azulen-1- carboxylate.

MSTR 1



G1 = (1) 23



G2 = (0-4) CH2
G3 = OH / 27



G4 = alkyl <containing 1-15 C>
(opt. substd. by (1-3) G5)
G5 = OPh
G15 = 58



G16 = NH
Patent location: claim 1
Note: and physiologically acceptable salts and solvates

L67 ANSWER 19 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 132:22824 MARPAT Full-text
TITLE: synthesis and dosages of fused phenoxymethylcarbapenem antibacterials
INVENTOR(S): Dininno, Frank P.; Dykstra, Kevin D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962907	A1	19991209	WO 1999-US12042	19990528
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20010011086	A1	20010802	US 1999-317790	19990524
US 6284753	B2	20010904		
CA 2333658	A1	19991209	CA 1999-2333658	19990528
AU 9942240	A	19991220	AU 1999-42240	19990528
EP 1086104	A1	20010328	EP 1999-926080	19990528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002517395	T	20020618	JP 2000-552118	19990528
PRIORITY APPLN. INFO.:			US 1998-87772P	19980602
			WO 1999-US12042	19990528

GI



AB Synthesis and dosages of fused phenoxymethylcarbapenem antibacterials (I) [R1 = H, Me; M = H, anion, ester, protecting group; P = H, (un)substituted OH, F; X = bond, (un)substituted CH2, O, (un)substituted S, (un)substituted CO, (un)substituted NH; Z = (E)-CH=CH, -C.tplbond.C-; R = (un)substituted NH2, (un)substituted OH, (un)substituted SH, (un)substituted CO2H, (un)substituted CONH2, (un)substituted SO2NH2, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted azonioheterocycle] is disclosed. Pharmaceutical compns. of I and methods of use are also included.

MSTR 1



G10 = 140



G11 = 106



G22 = Ph
G23 = O
G30 = 166



Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: substitution is restricted
Stereochemistry: CH=CH in G4 - trans

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 20 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 130:338120 MARPAT Full-text
TITLE: Preparation of 3-carbamoylalkoxy-2-aryloxypropionates and analogs as endothelin receptor antagonists
INVENTOR(S): Amberg, Wilhelm; Jansen, Rolf; Hergenroder, Stefan; Raschack, Manfred; Unger, Liliane
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9923078	A2	19990514	WO 1998-EP6571	19981016
WO 9923078	A3	19990910		
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19752904	A1	19990715	DE 1997-19752904	19971128
DE 19809376	A1	19990909	DE 1998-19809376	19980305
CA 2307770	A1	19990514	CA 1998-2307770	19981016
AU 9922661	A	19990524	AU 1999-22661	19981016
EP 1027338	A2	20000816	EP 1998-966230	19981016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9814951	A	20001003	BR 1998-14951	19981016
TR 200001182	T2	20001121	TR 2000-1182	19981016
JP 2001521927	T	20011113	JP 2000-518953	19981016
HU 2001000054	A2	20020228	HU 2001-54	19981016
HU 2001000054	A3	20020328		
NZ 504316	A	20021220	NZ 1998-504316	19981016
ZA 9809923	A	20000502	ZA 1998-9923	19981030
MX 200003322	A	20001110	MX 2000-3322	20000405
US 6509341	B1	20030121	US 2000-529860	20000420
NO 2000002124	A	20000426	NO 2000-2124	20000426
BG 104396	A	20010228	BG 2000-104396	20000502
PRIORITY APPLN. INFO.:			DE 1997-19748238	19971031
			DE 1997-19752904	19971128
			DE 1998-19809376	19980305
			WO 1998-EP6571	19981016

GI



I

AB Title compds. [I; R = OCHR1CR4R5Z1CR6R7R8; R1 = tetrazolyl or COR9; R2,R3 = H, OH, (di)(alkyl)amino, alkyl, etc.; R4,R5 = (un)substituted Ph or -naphthyl; R4R5 = C6H4C6H4, C6H4OC6H4, etc.; R6 = (un)substituted CONH2 or carboxamidoalkyl; R7,R8 = H or alkyl; R9 = OH, alkoxy, OCH2Ph, heteroaryl, etc,; X,Y = N or CH; Z = N or CR12; R12 = H, halo, alkyl; R2R12,R3R12 = atoms to complete a ring; Z1 = O or S] were prepared Thus, PhCH2OCH2CO2H was amidated by Bu2NH and the deprotected product condensed with Me 3,3-diphenyloxirane-2-carboxylate to give, after sapon and etherification, I [R = Bu2NCOCH2OCPh2CH(CO2H)O, R2 = R3 = Me, X = Y = N, Z =CH]. Data for biol. activity of I were given.

MSTR 1



G1 = 14



G2 = OH
G20 = 174

G22 = bond
G29 = 161



G30 = O
G34 = 165



G35 = Ph (opt. substd. by 1 or more G33)
Derivative: and physiologically acceptable salts
Patent location: claim 1
Stereochemistry: and enantiomers and diastereoisomers

MSTR 2



G1 = 14



G2 = OH
G20 = 174



G22 = bond
G29 = 161



G30 = O
G34 = 165



G35 = Ph (opt. substd. by 1 or more G33)
Patent location: claim 9

L67 ANSWER 21 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 130:267266 MARPAT Full-text
TITLE: Preparation of aryloxymethyl carbapenem antibacterials
INVENTOR(S): Dininno, Frank P.; Chen, Helen
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9914217	A1	19990325	WO 1998-US19015	19980914
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304267	A1	19990325	CA 1998-2304267	19980914
AU 9897742	A	19990405	AU 1998-97742	19980914
EP 1023293	A1	20000802	EP 1998-951912	19980914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002503638	T	20020205	JP 2000-511766	19980914
US 6277843	B1	20010821	US 1999-421078	19991019
PRIORITY APPLN. INFO.:			US 1997-59111P	19970917
			GB 1998-6433	19980325
			US 1998-133196	19980813
			WO 1998-US19015	19980914

GI



I



II

AB Carbapenems I [R1 = H, Me; M = H, anion; P = H, OH, F, OH, protected hydroxyl; X = CH2, C(R)2, C:CR2O, S(O)x, CO, (CO)2, OCO, NR; R = H, CN, NO2, halogen, etc.; x = 0, 1, 2] were prepared and formulated for use as antibacterial agents (no data) which are less susceptible to attack by a renal enzyme, dehydropeptidase (DHP). Thus, I (R1 = Me, M = Na, P = OH, X = S, R = H) was prepared starting from bis-allyl protected carbinol II and 1-hydroxydibenzothiophene.

MSTR 1



G6 = 113 / 116



G7 = 118 / 121



G8 = 108 / 111 / 175



G14 = O
G15 = (1-3) CH2
G16 = 127



G21 = Ph (opt. substd.)
G6 +G7 = 44



Derivative: or salts or hydrates
Patent location: claim 1
Note: additional ring formation also claimed

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 22 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 131:165311 MARPAT Full-text
TITLE: New carboxylic acid derivatives with 5-substituted pyrimidine ring, their preparation and use as endothelin receptor antagonists
INVENTOR(S): Amberg, Wilhelm; Jansen, Rolf; Kling, Andreas; Klinge, Dagmar; Riechers, Hartmut; Hergenroeder, Stefan; Raschack, Manfred; Unger, Liliane
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19806438	A1	19990819	DE 1998-19806438	19980217
CA 2321182	A1	19990826	CA 1999-2321182	19990205
WO 9942453	A1	19990826	WO 1999-EP776	19990205
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9930271	A	19990906	AU 1999-30271	19990205
BR 9907911	A	20001024	BR 1999-7911	19990205

TR 200002376	T2	20001221	TR 2000-2376	19990205
EP 1066268	A1	20010110	EP 1999-911657	19990205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
JP 2002503726	T	20020205	JP 2000-532405	19990205
HU 2001000957	A2	20020228	HU 2001-957	19990205
TW 579376	B	20040311	TW 1999-88102031	19990210
ZA 9901214	A	20000816	ZA 1999-1214	19990216
MX 2000PA06463	A	20010219	MX 2000-PA6463	20000629
BG 104577	A	20010330	BG 2000-104577	20000704
IN 2000CN00227	A	20050304	IN 2000-CN227	20000728
NO 2000004075	A	20000815	NO 2000-4075	20000815
HR 2000000602	A1	20010630	HR 2000-602	20000913
PRIORITY APPLN. INFO.:			DE 1998-19806438	19980217
			WO 1999-EP776	19990205

GI



I

AB The title compds. [I; R1 = tetrazolyl, C(O)R; R = OR7, (substituted) N-linked 5-membered heteroarom. residue, O(CH2)pS(:O)kR8, NHSO2R9; R7 = H, cation, (substituted) C3-8 cycloalkyl, (substituted) C1-8 alkyl, (substituted) Ph, (substituted) CH2Ph, C3-6 (halo)alkenyl, C3-6 (halo)alkynyl; R8, R9 = (substituted) C1-4 alkyl, (substituted) C3-8 cycloalkyl, (substituted) C3-6 alkenyl, (substituted) C3-6 alkynyl, (substituted) Ph; k = 0-2; p = 1-4; R2, R3 = H, OH, (substituted) amino, halo, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, alkoxy, etc.; R4, R5 = (substituted) Ph, (substituted) naphthyl, C3-7 cycloalkyl, etc.; R6 = H, (substituted) C1-8 alkyl, (substituted) C3-6 alkenyl, (substituted) C3-6 alkynyl, (substituted) C3-8 cycloalkyl, (substituted) Ph, (substituted) naphthyl, (substituted) 5- or 6-membered heteroarom. residue; X = halo, C1-4 haloalkyl, OH; Z = O, S, single bond], their enantiomers, diastereomers, and physiol. compatible salts are useful as endothelin receptor antagonists for treatment of diseases associated with elevated endothelin levels, such as chronic cardiac insufficiency, restenosis, hypertension, acute or chronic kidney failure, cerebral ischemia, asthma, benign prostate hyperplasia, and prostate cancer. Thus, Me 2-hydroxy-3-methoxy-3,3-diphenylpropionate reacted with NaH and 4,6-dimethoxy-5-fluoro-2-methylsulfonylpyrimidine in DMF to produce I (R1 = CO2Me, R2 = R3 = OMe, R4 = R5 = Ph, R6 = Me, X = F, Z = O), which was saponified to the corresponding acid (R1 = CO2H) (II). II bound to endothelin ETA and ETB receptors with Ki 7.4 and 1200 nM, resp.

MSTR 1D



G1 = 14



G2 = OH
G26 = bond
G27 = alkyl <containing 1-8 C>
(opt. substd. by 1 or more G28)
G28 = OPh
G35 = S
Derivative: and physiologically acceptable salts
Patent location: claim 1
Note: substitution is restricted
Note: additional ring formation also claimed
Stereochemistry: and enantiomeric and diastereomeric forms

L67 ANSWER 23 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 130:81517 MARPAT Full-text
TITLE: New β-amino and β-azido carboxylic acid derivatives for use as endothelin receptor antagonists
INVENTOR(S): Amberg, Wilhelm; Kling, Andreas; Klinge, Dagmar; Riechers, Hartmut; Hergenroder, Stefan; Raschack, Manfred; Unger, Liliane
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858916	A1	19981230	WO 1998-EP3366	19980605
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19726146	A1	19981224	DE 1997-19726146	19970619
CA 2294050	A1	19981230	CA 1998-2294050	19980605

AU 9882133	A	19990104	AU 1998-82133	19980605
EP 994861	A1	20000426	EP 1998-932123	19980605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, SI, FI, RO				
TR 9903159	T2	20000721	TR 1999-3159	19980605
BR 9810182	A	20000808	BR 1998-10182	19980605
HU 2000002714	A2	20010528	HU 2000-2714	19980605
HU 2000002714	A3	20010730		
JP 2002504130	T	20020205	JP 1999-503667	19980605
NZ 502319	A	20020301	NZ 1998-502319	19980605
ZA 9805277	A	19991220	ZA 1998-5277	19980618
IN 1998MA01342	A	20050304	IN 1998-MA1342	19980618
MX 9911504	A	20000430	MX 1999-11504	19991210
BG 104022	A	20010430	BG 1999-104022	19991216
NO 9906268	A	19991217	NO 1999-6268	19991217
PRIORITY APPLN. INFO.:			DE 1997-19726146	19970619
			WO 1998-EP3366	19980605

GI



I

AB Title compds. ACR2R3CHR1OR [R = 6-membered heterocycle; R1 = tetrazolyl, (un)substituted CO2H, CONH2, acyl; R2, R3 = (un)substituted or fused Ph, naphthyl; A = (un)substituted NH2, N3] were prepared for use as endothelin receptor antagonists. Thus, Me 3,3-diphenyl-2,3-epoxypropionate was treated with NaN3, followed by 4-methoxy-6-methyl-2- methanesulfonylpyrimidine to give the azido ester I [R4 = N3, R5 = OMe]. The azide was reduced and the ester group hydrolyzed to give I [R4 = NH2, R5 = OH] which had an endothelin ETA receptor binding affinity of 300 nM.

MSTR 1



G1 = 68-9 69-7



G3 = OH
G12 = 111



G23 = 85



G24 = bond
G31 = 145



Patent location: claim 1
Note: also incorporates claim 8

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 24 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 129:275935 MARPAT Full-text
TITLE: Novel pyrimidine- and triazine-containing carboxylic acid derivatives, their preparation, and use as endothelin receptor antagonists in treating cancer
INVENTOR(S): Romerdahl, Cynthia A.
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841206	A1	19980924	WO 1998-US4596	19980309
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6030975	A	20000229	US 1997-818622	19970314
CA 2283732	A1	19980924	CA 1998-2283732	19980309
AU 9866946	A	19981012	AU 1998-66946	19980309

AU 744019	B2	20020214		
EP 969841	A1	20000112	EP 1998-909067	19980309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9808263	A	20000516	BR 1998-8263	19980309
HU 2000002249	A2	20010528	HU 2000-2249	19980309
HU 2000002249	A3	20011128		
JP 2001517220	T	20011002	JP 1998-540573	19980309
IN 1998MA00509	A	20050304	IN 1998-MA509	19980312
ZA 9802136	A	19990913	ZA 1998-2136	19980313
NO 9904426	A	19991112	NO 1999-4426	19990913
PRIORITY APPLN. INFO.:			US 1997-818622	19970314
			WO 1998-US4596	19980309

GI



I



II

AB The invention provides a method for treating cancer, wherein the cancer is a tumor in which endothelin (ET) is upregulated (e.g. tumors of the prostate, lung, liver, breast, brain, stomach, colon, endometrium, testicle, thyroid, pituitary, bladder, kidney, pancreas and meninges), by administering a compound I [R = CHO, tetrazolyl, cyano, CO2H or its hydrolyzable derivs.; R2 = H, OH, (di)(alkyl)amino, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio; X = N, CH, C-alkyl, or forms a 5- or 6-ring to R3; R3 = groups given for R2, or NHO-alkyl, or forms 5- or 6-ring to X; R4, R5 = (un)substituted Ph, naphthyl, or certain fused derivs.; or R4 = a wide variety of possible substituents and R5 = H, alk(en/yn)yl, cycloalkyl, haloalkyl, Ph, etc.; or R4R5 forms (un)substituted 3- to 8-ring; R6 = H, (un)substituted alk(en/yn)yl, cycloalkyl, Ph, naphthyl, heteroaryl; Y, Z = S, O, bond; with provisos]. Over 150 compds. were prepared For instance, methanolysis of Me 3,3-diphenyl-2,3-epoxypropionate in the presence of BF3.OEt2 gave 88% Me 2-hydroxy-3-methoxy-3,3-diphenylpropionate, which was etherified with 4,6-dimethoxy-2-(methylsulfonyl)pyrimidine to give 82% title compound II. At 150 mg/kg/day i.p. in mice in the DU-145 prostate tumor model, II reduced mean tumor weight to 33% of control after 10 days.

MSTR 1C



G1 = CO2H
G11 = o-C6H4
G12 = o-C6H4
G13 = bond
G15 = 235



G16 = OPh (opt. substd.)
G22 = O
G23 = alkyl <containing 1-8 C>
(opt. substd. by 1 or more G16)
G24 = bond
Patent location: claim 1

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 25 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 128:217378 MARPAT Full-text
TITLE: Preparation of α-(azinyloxy)diarylpropionates as ETA/ETB antagonists
INVENTOR(S): Amberg, Wilhelm; Jansen, Rolf; Kling, Andreas; Klinge, Dagmar; Riechers, Hartmut; Hergenroder, Stefan; Raschack, Manfred; Unger, Liliane
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9809953	A2	19980312	WO 1997-EP4688	19970902
WO 9809953	A3	19981029		
W: AL, AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19636046	A1	19980312	DE 1996-19636046	19960905
CA 2265504	A1	19980312	CA 1997-2265504	19970902
AU 9745524	A	19980326	AU 1997-45524	19970902
AU 736414	B2	20010726		
EP 929529	A2	19990721	EP 1997-943819	19970902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, SI, FI, RO				
BR 9711693	A	19990824	BR 1997-11693	19970902
CN 1236362	A	19991124	CN 1997-199458	19970902
JP 2000517329	T	20001226	JP 1998-512203	19970902
HU 2000000664	A2	20010428	HU 2000-664	19970902
HU 2000000664	A3	20010730		
ZA 9707946	A	19990304	ZA 1997-7946	19970904
IN 1997MA01961	A	20050304	IN 1997-MA1961	19970904
US 6670367	B1	20031230	US 1999-254137	19990301

NO 9901079	A	19990504	NO 1999-1079	19990304
NO 312674	B1	20020617		
BG 103258	A	20001229	BG 1999-103258	19990316
PRIORITY APPLN. INFO.:			DE 1996-19636046	19960905
			WO 1997-EP4688	19970902

GI



II



III

AB R6QWCR4R5CH(OR)R1 [I; Q = C2-4 spacer (sic); R = cyclic group II; R1 = CO2R7, CONHSO2R9, CONR13R14, etc.; R2,R3 = H, halo, alkyl, alkoxy, etc.; R4,R5 = (un)substituted Ph, -naphthyl, -biphenylyl, etc.; R6 = cycloalkyl, Ph, heteroaryl, etc.; R7 = H, alkyl, phenyl(methyl), etc.; R9 = alk(en)yl, phenyl(alkyl), etc.; R13,R14 = H, alkyl, Ph, CH2Ph, etc.; W = O or S; X,Y = N or CH; Z = N, (un)substituted CH, etc.] were prepared Thus, (4-EtC6H4)2CO was cyclocondensed with ClCH2CO2Me and the resulting epoxide condensed with 3,4-(MeO)2C6H3CH2CH2OH to give 3,4- (MeO)2C6H3CH2CH2OC(C6H4Et-4)2CH(OH)CO2Me which was saponified and the product etherified by 4-methoxy-6-methyl-2-methylsulfonylpyrimidine to give title compound III. Data for biol. activity of I were given.

MSTR 1



G1 = 14



G2 = OH
G20 = 165



G22 = bond
G29 = Ph (opt. substd. by 1 or more G38)
G30 = O
G31 = 116-12 118-10



Derivative: and physiologically acceptable salts
Patent location: claim 1
Stereochemistry: and enantiomers and diastereoisomers

L67 ANSWER 26 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 125:58534 MARPAT Full-text
TITLE: Preparation of pyrimidine- and triazine-derivative endothelin receptor antagonists
INVENTOR(S): Riechers, Hartmut; Klinge, Dagmar; Amberg, Wilhelm; Kling, Andreas; Mueller, Stefan; Baumann, Ernst; Rheinheimer, Joachim; Vogelbacher, Uwe Josef; Wernet, Wolfgang; et al.
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19533023	A1	19960418	DE 1995-19533023	19950907
DE 19533023	B4	20070516		
CA 2201785	A1	19960425	CA 1995-2201785	19951007
CA 2201785	C	20060829		
WO 9611914	A1	19960425	WO 1995-EP3963	19951007
W: AU, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9538045	A	19960506	AU 1995-38045	19951007
AU 688611	B2	19980312		
EP 785926	A1	19970730	EP 1995-935916	19951007
EP 785926	B1	20010822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1160396	A	19970924	CN 1995-195655	19951007
BR 9509338	A	19971104	BR 1995-9338	19951007
HU 77443	A2	19980428	HU 1997-1975	19951007
HU 220621	B1	20020328		
JP 10507190	T	19980714	JP 1996-512911	19951007
JP 3957748	B2	20070815		
EP 1110952	A1	20010627	EP 2001-103889	19951007
EP 1110952	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 204568	T	20010915	AT 1995-935916	19951007
ES 2162942	T3	20020116	ES 1995-935916	19951007
PT 785926	T	20020228	PT 1995-935916	19951007

RU 2180335	C2	20020310	RU 1997-107617 19951007
PL 186850	B1	20040331	PL 1995-319655 19951007
CN 1513844	A	20040721	CN 2004-10002783 19951007
AT 277911	T	20041015	AT 2001-103889 19951007
CZ 294603	B6	20050216	CZ 1997-1132 19951007
ES 2226996	T3	20050401	ES 2001-103889 19951007
CN 1923820	A	20070307	CN 2006-10099954 19951007
IL 115560	A	20030212	IL 1995-115560 19951011
ZA 9508642	A	19970414	ZA 1995-8642 19951013
HR 950517	B1	20040630	HR 1995-517 19951013
TW 577880	B	20040301	TW 1995-84110900 19951017
US 5932730	A	19990803	US 1997-809699 19970327
FI 9701529	A	19970411	FI 1997-1529 19970411
NO 9701675	A	19970610	NO 1997-1675 19970411
NO 308846	B1	20001106	
US 5969134	A	19991019	US 1998-184152 19981102
US 6197958	B1	20010306	US 1999-309770 19990511
US 20020052495	A1	20020502	US 2000-748184 20001227
US 6600043	B2	20030729	
GR 3036931	T3	20020131	GR 2001-401798 20011018
US 7109205	B2	20060919	US 2003-602275 20030624
US 20040092742	A1	20040513	
HR 2004000364	B1	20060930	HR 2004-364 20040422
HK 1066541	A1	20070601	HK 2004-109463 20041201
US 20060160808	A1	20060720	US 2006-377879 20060316
US 7119097	B2	20061010	
US 20060276645	A1	20061207	US 2006-502257 20060810
US 20060276474	A1	20061207	US 2006-502293 20060810
JP 2007126488	A	20070524	JP 2007-40759 20070221
JP 2007137892	A	20070607	JP 2007-40760 20070221
JP 2007137893	A	20070607	JP 2007-40761 20070221
JP 2007169295	A	20070705	JP 2007-40758 20070221
US 20070203338	A1	20070830	US 2007-789630 20070425

PRIORITY APPLN. INFO.:

DE 1994-4436851 19941014
DE 1995-19533023 19950907
CN 2004-10002783 19951007
EP 1995-935916 19951007
JP 1996-512911 19951007
WO 1995-EP3963 19951007
US 1997-809699 19970327
US 1998-184152 19981102
US 1999-309770 19990511
US 2000-748184 20001227
US 2003-602275 20030624
US 2006-502257 20060810

OTHER SOURCE(S): CASREACT 125:58534

GI



I



II

AB The title compds. [I; R = CHO, tetrazolyl, CN, CO2H, groups cleavable to CO2H; R2 = (un)substituted NH2, halogen, (un)substituted alkyl, etc.; R3 = H, OH, (un)substituted NH2, halogen, (un)substituted alkyl, etc.; R4, R5 = (un)substituted Ph or naphthyl; R6 = H, alkyl, alkenyl, alkynyl, alkylcarbonyl, (un)substituted Ph, etc.; X = N, (un)substituted CH; Y = direct bond, S, O; Z = S, O, SO, SO2, direct bond], useful as endothelin receptor antagonists, are prepared Thus, pyrimidine derivative II, m.p. 167°, demonstrated a Ki ETA of 6 nM.

MSTR 1B



G1 = CO2H
G12 = 52



G15 = bond
G26 = alkyl <containing 1-8 C>
(opt. substd. by 1 or more G27)
G27 = OPh (substd. by 1 or more G28)
G33 = bond
G34 = S
Patent location: claim 1
Note: substitution is restricted

L67 ANSWER 27 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 124:117346 MARPAT Full-text
TITLE: Preparation of indeno[1,2-e]-1,2,4-triazolo[4,3-a]pyrazin-4-ones as AMPA and NMDA receptor antagonists
INVENTOR(S): Aloup, Jean-Claude; Audiau, Francois; Barreau, Michel; Damour, Dominique; Genevois-Borella, Arielle; Jimonet, Patrick; Mignani, Serge; Ribeill, Yves
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9526351 A1 19951005 WO 1995-FR360 19950323
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
FR 2717814 A1 19950929 FR 1994-3584 19940328
FR 2717814 B1 19960426
AU 9521415 A 19951017 AU 1995-21415 19950323
EP 752993 A1 19970115 EP 1995-914406 19950323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 09510729 T 19971028 JP 1995-524997 19950323
ZA 9502526 A 19960115 ZA 1995-2526 19950328
PRIORITY APPLN. INFO.: FR 1994-3584 19940328
WO 1995-FR360 19950323

GI



I

AB Title compds. [I; R1,R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, (cyclo)alkyl, phenyl(alkyl), NH2, heterocyclyl; Z = alkylimino, C(:X), CR4R5, CHR6; R4 = (heterocyclyl)alkyl, phenylalkyl, etc.; R5 = (di)(alkyl)amino, alkoxycarbonyl(amino), CO2R7, etc.; R6 = NHCHO, alkoxycarbonyl(alkyl), phenylalkyl, etc.; R7 = H, alkyl; X = O, alkoxyimino, CHR10, NR7, etc.; R10 = OH, CO2R7-substituted alkyl, heterocyclyl, Ph, etc.] were prepared Thus, 1-indanone was converted in 3 steps to 2-amino-1-indanone which was acylated by ClCOCO2Et and the product cyclocondensed with NH4OAc to give 1,4-dihydro-5H-indeno[1,2- b]pyrazine-2,3-dione. The latter was condensed with H2NNH2 and the product cyclized to give I (R1 = R2 = H, Z = CH2). I had inhibitory activity (sic) of ≤100μM against ligand binding to AMPA and NMDA receptors in vitro.

MSTR 2



G1 = 28



G3 = NH
G4 = 33



G6 = 37



G7 = NH
G8 = 44 / Ph (opt. substd. by 1 or more G13)



G9 = alkylene <containing 1-6 C>
G19 = 90

G20 = 92



G23 = 99 / 103

G24 = 101



G25 = OH
G26 = 108



Patent location: claim 7
Note: also incorporates claim 8

L67 ANSWER 28 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 124:146196 MARPAT Full-text
TITLE: Preparation of 5H-indeno[1,2-b]pyrazine-2,3-diones as AMPA and NMDA receptor antagonists
INVENTOR(S): Aloup, Jean-Claude; Audiau, Francois; Barreau, Michel; Damour, Dominique; Genevois-Borella, Arielle; Jimonet, Patrick; Magnani, Serge; Ribeill, Yves
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526342	A1	19951005	WO 1995-FR359	19950323
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2717805	A1	19950929	FR 1994-3583	19940328
FR 2717805	B1	19960510		
CA 2184754	A1	19951005	CA 1995-2184754	19950302
AU 9521414	A	19951017	AU 1995-21414	19950323
AU 692853	B2	19980618		
EP 752988	A1	19970115	EP 1995-914405	19950323
EP 752988	B1	19990526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 75307	A2	19970528	HU 1996-2658	19950323
BR 9507446	A	19970812	BR 1995-7446	19950323
JP 09510728	T	19971028	JP 1995-524996	19950323
JP 3942631	B2	20070711		
AT 180476	T	19990615	AT 1995-914405	19950323
ES 2134460	T3	19991001	ES 1995-914405	19950323
ZA 9502525	A	19960115	ZA 1995-2525	19950328
NO 9604059	A	19960926	NO 1996-4059	19960926
NO 308075	B1	20000717		
FI 9603881	A	19960927	FI 1996-3881	19960927
FI 112219	B1	20031114		
US 5922716	A	19990713	US 1996-714164	19960927
PRIORITY APPLN. INFO.:			FR 1994-3583	19940328
			WO 1995-FR359	19950323

OTHER SOURCE(S): CASREACT 124:146196

GI



I

AB Title compds. [I; R1,R2 = H, halo, alkyl, alkoxy, etc.; X = O, NOH, (ar)alkoxyimino; Z = alkylimino, CR4R5, CHR6. CO, C:NOH, etc.; R4 = (phenyl)alkyl, heterocyclylalkyl; R5 = (heterocyclyl)alkyl, (di)(alkyl)amino, NHCHO, etc.; R6 = H, OH, alkyl, NH2, etc.] were prepared Thus, 1-indanone oxime p-toluenesulfonate was treated with NaOEt and the aminoketone product amidated with ClCOCO2Et to give, after cyclocondensation with NH4OAc, I (R1 = R2 = H, X = O, Z = CH2). I had in vitro inhibitory activity (sic) against ligand binding at AMPA and NMDA receptors of ≤100μM.

MSTR 1



G1 = 43



G5 = alkylene <containing 1-6 C>
G13 = OH
G16 = 62



G35 = 138



G38 = Ph (opt. substd. by 1 or more G9)
G39 = NH
Derivative: and salts or tautomers
Patent location: claim 1
Note: also incorporates claims 16, 33, 36, and 43
Note: substitution is restricted
Stereochemistry: and isomers, diastereoisomers, and enatiomers

MSTR 2



G1 = 43



G5 = alkylene <containing 1-6 C>
G13 = OH
G16 = 62



G35 = 138



G38 = Ph (opt. substd. by 1 or more G9)
G39 = NH
Patent location: claim 7

Note: substitution is restricted

L67 ANSWER 29 OF 29 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 122:81372 MARPAT Full-text
TITLE: Preparation of cyclic urea derivatives as drugs
INVENTOR(S): Himmelsbach, Frank; Austel, Volkhard; Linz, Guenter; Pieper, Helmut; Guth, Brian; Mueller, Thomas; Weisenberger, Johannes
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 125 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 587134	A2	19940316	EP 1993-114401	19930908
EP 587134	A3	19940706		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4230470	A1	19940414	DE 1992-4230470	19920911
DE 4302052	A1	19940728	DE 1993-4302052	19930126
DE 4309213	A1	19940929	DE 1993-4309213	19930322
FI 9303942	A	19940312	FI 1993-3942	19930909
CA 2105934	A1	19940312	CA 1993-2105934	19930910
NO 9303248	A	19940314	NO 1993-3248	19930910
AU 9346249	A	19940324	AU 1993-46249	19930910
ZA 9306689	A	19950310	ZA 1993-6689	19930910
HU 71496	A2	19951128	HU 1993-2577	19930910
US 5681841	A	19971028	US 1993-120008	19930910
CN 1092769	A	19940928	CN 1993-114711	19930911
JP 06263740	A	19940920	JP 1993-226864	19930913
US 5880284	A	19990309	US 1997-864528	19970528
PRIORITY APPLN. INFO.:			DE 1992-4230470	19920911
			DE 1993-4302052	19930126
			DE 1993-4309213	19930322
			US 1993-120008	19930910

GI



I

AB Title compds. [I; A = e.g., acylamidino, etc.; B = e.g., 1,4-azacycloheptylene, 1,4- piperidinylene, 1,4-piperazinylene, etc.; C = e.g., 1,4- piperidinylene, 1,2,3,4-tetrahydro-2,6-naphthylene, 1,4-bicyclo[2.2.2]octanylene, etc.; D = alkylene, 1,3-phenylene, 1,4-cyclohexylene, etc.; E = bond, CH:CH, alkylene, etc.; F = CO2H, alkoxycarbonyl, etc.; X = e.g., N-cyanocarbimino, etc.; Y = e.g., 1,2-cyclohexylene] were prepared as cell aggregation inhibitors. Thus, 2-(4-amidinophenyl)-4-[4-[2-(cyclohexyloxycarbonyl)ethyl]phenyl]-5-methyl- 4H-

1,2,4-triazol-3-one hydrochloride inhibited ex vivo thrombocyte aggregation in blood from rhesus monkeys after oral administration of 1mg/kg.

MSTR 3



G5 = 63



G8 = p-C6H4
G12 = 272



G13 = OH
G21 = 417-3 423-268



G22 = alkylene <containing 2-4 C> (opt. substd. by G20)
Patent location: claim 11

FILE 'BEILSTEIN' ENTERED AT 17:24:39 ON 21 JUL 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
*** FILE CONTAINS 10.322,808 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.

```
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

*********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.               *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE  *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE         *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                       *
* FOR PRICE INFORMATION SEE HELP COST                               *
*********************************************************************

>>> Price change as of January 1st, 2008: Connect Time and Structure
    Search fees re-introduced. See NEWS and HELP COST <<<


L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L6          161 SEA FILE=BEILSTEIN SSS FUL L1
L7           98 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L6 AND BABSAN/FA
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L12         161 SEA FILE=BEILSTEIN SUB=L6 SSS FUL L10
L13          63 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L12 NOT L7
L16          63 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L13 AND 2007?/DED
L22           0 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L13 NOT L16



L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L6          161 SEA FILE=BEILSTEIN SSS FUL L1
L7           98 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L6 AND BABSAN/FA
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L12         161 SEA FILE=BEILSTEIN SUB=L6 SSS FUL L10
L13          63 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L12 NOT L7
L16          63 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L13 AND 2007?/DED
```

L16 ANSWER 1 OF 63 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	10744287
Chemical Name (CN):	(5-<3-<2-propyl-4-(4,5,6,7-tetrahydro-benzothiazol-2-yl)-phenoxy>-propoxy>-indan-1-yl)-acetic acid ethyl ester
Autonom Name (AUN):	(5-<3-<2-propyl-4-(4,5,6,7-tetrahydro-benzothiazol-2-yl)-phenoxy>-propoxy>-indan-1-yl)-acetic acid ethyl ester
Molec. Formula (MF):	C32 H39 N O4 S
Molecular Weight (MW):	533.72
Lawson Number (LN):	31035, 11780, 523, 298
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	8997990
Tautomer ID (TAUTID):	10009432
Entry Date (DED):	2007/07/13
Update Date (DUPD):	2007/07/13



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence

RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Cruz, Fernando E. Dela; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; et al., J. Med. Chem., CODEN: JMCMAR, SIR50(5), <2007>, 984 - 1000; BABS-6653078

L16 ANSWER 20 OF 63 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	10736971
Chemical Name (CN):	(5-<3-<4-(5-acetyl-4-methyl-thiazol-2-yl)-2-methoxy-phenoxy>-propoxy>-indan-1-yl)-acetic acid ethyl ester
Autonom Name (AUN):	(5-<3-<4-(5-acetyl-4-methyl-thiazol-2-yl)-2-methoxy-phenoxy>-propoxy>-indan-1-yl)-acetic acid ethyl ester
Molec. Formula (MF):	C29 H33 N O6 S
Molecular Weight (MW):	523.64
Lawson Number (LN):	31346, 11780, 523, 298, 289
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	8993111
Tautomer ID (TAUTID):	10016165
Entry Date (DED):	2007/07/13
Update Date (DUPD):	2007/07/13



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	5

FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Cruz, Fernando E. Dela; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; et al., J. Med. Chem., CODEN: JMCMAR, SIR50(5), <2007>, 984 - 1000; BABS-6653078

L16 ANSWER 40 OF 63 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	10727121
Chemical Name (CN):	<5-<3-(4-cyano-2-propyl-phenoxy)-propoxy>-indan-1-yl>-acetic acid ethyl ester
Autonom Name (AUN):	<5-<3-(4-cyano-2-propyl-phenoxy)-propoxy>-indan-1-yl>-acetic acid ethyl ester
Molec. Formula (MF):	C26 H31 N O4
Molecular Weight (MW):	421.54
Lawson Number (LN):	11780, 11713, 523, 298
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	8982941
Tautomer ID (TAUTID):	9991554
Entry Date (DED):	2007/07/13
Update Date (DUPD):	2007/07/13



Field Availability:

Code	Name	Occurrence

BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	3
RXREA	Substance is Reaction Reactant	2
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Cruz, Fernando E. Dela; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; et al., J. Med. Chem., CODEN: JMCMAR, SIR50(5), <2007>, 984 - 1000; BABS-6653078

L16 ANSWER 50 OF 63 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	10719480
Chemical Name (CN):	<5-<3-(biphenyl-4-yloxy)-propoxy>-indan-1-yl>-acetic acid ethyl ester
Autonom Name (AUN):	<5-<3-(biphenyl-4-yloxy)-propoxy>-indan-1-yl>-acetic acid ethyl ester
Molec. Formula (MF):	C28 H30 O4
Molecular Weight (MW):	430.54
Lawson Number (LN):	11780, 5519, 523, 298
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	8978652
Tautomer ID (TAUTID):	9989222
Entry Date (DED):	2007/07/13
Update Date (DUPD):	2007/07/13



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Cruz, Fernando E. Dela; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; et al., J. Med. Chem., CODEN: JMCMAR, SIR50(5), <2007>, 984 - 1000; BABS-6653078

L16 ANSWER 60 OF 63 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	10711494
Chemical Name (CN):	<5-<3-(4-methoxy-phenoxy)-propoxy>-indan-1-yl>-acetic acid ethyl ester
Autonom Name (AUN):	<5-<3-(4-methoxy-phenoxy)-propoxy>-indan-1-yl>-acetic acid ethyl ester
Molec. Formula (MF):	C23 H28 O5
Molecular Weight (MW):	384.47
Lawson Number (LN):	11780, 5908, 523, 298, 289
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	8968885
Tautomer ID (TAUTID):	9981370
Entry Date (DED):	2007/07/13
Update Date (DUPD):	2007/07/13



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	5
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Rudolph, Joachim; Chen, Libing; Majumdar, Dyuti; Bullock, William H.; Burns, Michael; Claus, Thomas; Cruz, Fernando E. Dela; Daly, Michelle; Ehrgott, Frederick J.; Johnson, Jeffrey S.; Livingston, James N.; et al., J. Med. Chem., CODEN: JMCMAR, SIR50(5), <2007>, 984 - 1000; BABS-6653078

```
=> d his full

     (FILE 'HOME' ENTERED AT 16:23:43 ON 21 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 16:23:52 ON 21 JUL 2008
L1             STRUCTURE UPLOADED
L2           7 SEA SSS SAM L1
               D SCA
L3         363 SEA SSS FUL L1
               SAVE TEMP L3 BIA630STR1L/A

     FILE 'ZCAPLUS' ENTERED AT 16:25:47 ON 21 JUL 2008
L4           6 SEA ABB=ON  PLU=ON  L3
               D SCA

     FILE 'BEILSTEIN' ENTERED AT 16:26:38 ON 21 JUL 2008
L5           6 SEA SSS SAM L1
L6         161 SEA SSS FUL L1
L7          98 SEA ABB=ON  PLU=ON  L6 AND BABSAN/FA
               SEL BABSAN

     FILE 'BABS' ENTERED AT 16:28:10 ON 21 JUL 2008
L8           1 SEA ABB=ON  PLU=ON  6653078/BABSAN
               D IALL

     FILE 'REGISTRY' ENTERED AT 16:37:22 ON 21 JUL 2008
L*** DEL       STRUCTURE UPLOADED
L*** DEL       STRUCTURE UPLOADED
L*** DEL     0 S L10

     FILE 'LREGISTRY' ENTERED AT 16:41:56 ON 21 JUL 2008
L*** DEL     0 S L10
L*** DEL     0 S L10 FULL

     FILE 'CAPLUS' ENTERED AT 16:42:35 ON 21 JUL 2008
               E US2006-334145 /APPS
L*** DEL     1 S US2006-334145 /AP
               D SCA
               SEL RN

     FILE 'REGISTRY' ENTERED AT 16:43:00 ON 21 JUL 2008
L*** DEL     7 S E1-E7
               D SCA
L*** DEL     1 S "(C13 H18 N2 O5 . C12 H25 N O4 SI . C9 H16 O4 . C6 H11 N O)X"
               D IDE

     FILE 'STNGUIDE' ENTERED AT 16:52:34 ON 21 JUL 2008

     FILE 'ZCAPLUS, BABS' ENTERED AT 16:52:40 ON 21 JUL 2008
L9           6 DUP REM L4 L8 (1 DUPLICATE REMOVED)
                 ANSWERS '1-6' FROM FILE ZCAPLUS

     FILE 'STNGUIDE' ENTERED AT 16:52:45 ON 21 JUL 2008

     FILE 'BEILSTEIN' ENTERED AT 16:54:31 ON 21 JUL 2008
L10            STRUCTURE UPLOADED
L11          6 SEA SUB=L6 SSS SAM L10
L12        161 SEA SUB=L6 SSS FUL L10
```

```
L13          63 SEA ABB=ON  PLU=ON  L12 NOT L7
                D IDE 10
L*** DEL      0 S L13 AND DED<20030000

     FILE 'STNGUIDE' ENTERED AT 16:58:10 ON 21 JUL 2008

     FILE 'BEILSTEIN' ENTERED AT 16:58:52 ON 21 JUL 2008
L14           0 SEA ABB=ON  PLU=ON  L13 AND RN/FA
L15           0 SEA ABB=ON  PLU=ON  L13 AND 2008?/DED
L16          63 SEA ABB=ON  PLU=ON  L13 AND 2007?/DED
L17           0 SEA ABB=ON  PLU=ON  L13 AND 2006?/DED
L18           0 SEA ABB=ON  PLU=ON  L13 AND 2005?/DED
L19           0 SEA ABB=ON  PLU=ON  L13 AND 2004?/DED
L20          63 SEA ABB=ON  PLU=ON  L13 AND 2007?/DUPD
L21           0 SEA ABB=ON  PLU=ON  L13 AND 2008?/DUPD
L22           0 SEA ABB=ON  PLU=ON  L13 NOT L16
                D L16 10 ALLREF
L23         823 SEA ABB=ON  PLU=ON  RUDOLPH J?/AU
L24           0 SEA ABB=ON  PLU=ON  L16 AND L23
L*** DEL      1 S 10739935/BRN
L*** DEL      0 S 107399!!/BRN
L*** DEL      0 S 107399##/BRN
L*** DEL      0 S 107399?/BRN

     FILE 'WPIX' ENTERED AT 17:07:00 ON 21 JUL 2008
L25           2 SEA SSS SAM L1
L26          41 SEA SSS FUL L1
L27           1 SEA ABB=ON  PLU=ON  L26/DCR

     FILE 'MARPAT' ENTERED AT 17:07:39 ON 21 JUL 2008
L28           0 SEA SSS SAM L1
L29          26 SEA SSS FUL L1

     FILE 'ZCAPLUS' ENTERED AT 17:09:57 ON 21 JUL 2008
L30          42 SEA ABB=ON  PLU=ON  CANTIN L?/AU
L31       14960 SEA ABB=ON  PLU=ON  CHOI S?/AU
L32        2383 SEA ABB=ON  PLU=ON  CLARK C?/AU
L33          24 SEA ABB=ON  PLU=ON  HENTEMANN M?/AU
L34        9485 SEA ABB=ON  PLU=ON  MA X?/AU
L35         494 SEA ABB=ON  PLU=ON  RUDOLPH J?/AU
L36        3094 SEA ABB=ON  PLU=ON  LIANG S?/AU
L37           9 SEA ABB=ON  PLU=ON  AKUCHE C?/AU
L38          45 SEA ABB=ON  PLU=ON  LAVOIE R?/AU
L39       27523 SEA ABB=ON  PLU=ON  CHEN L?/AU
L40         553 SEA ABB=ON  PLU=ON  MAJUMDAR D?/AU
L41          31 SEA ABB=ON  PLU=ON  WICKENS P?/AU
L42          12 SEA ABB=ON  PLU=ON  L30 AND (L31 OR L32 OR L33 OR L34 OR L35
                OR L36 OR L37 OR L38 OR L39 OR L40 OR L41)
L43          44 SEA ABB=ON  PLU=ON  L31 AND (L32 OR L33 OR L34 OR L35 OR L36
                OR L37 OR L38 OR L39 OR L40 OR L41)
L44           1 SEA ABB=ON  PLU=ON  L32 AND (L33 OR L34 OR L35 OR L36 OR L37
                OR L38 OR L39 OR L40 OR L41)
L45           6 SEA ABB=ON  PLU=ON  L33 AND (L34 OR L35 OR L36 OR L37 OR L38
                OR L39 OR L40 OR L41)
L46         137 SEA ABB=ON  PLU=ON  L34 AND (L35 OR L36 OR L37 OR L38 OR L39
                OR L40 OR L41)
L47          10 SEA ABB=ON  PLU=ON  L35 AND (L36 OR L37 OR L38 OR L39 OR L40
                OR L41)
L48          32 SEA ABB=ON  PLU=ON  L36 AND (L37 OR L38 OR L39 OR L40 OR L41)
L49           2 SEA ABB=ON  PLU=ON  L37 AND (L38 OR L39 OR L40 OR L41)
```

```
L50           3 SEA ABB=ON  PLU=ON  L38 AND (L39 OR L40 OR L41)
L51           9 SEA ABB=ON  PLU=ON  L39 AND (L40 OR L41)
L52           4 SEA ABB=ON  PLU=ON  L40 AND L41
L53          12 SEA ABB=ON  PLU=ON  L42 AND (L43 OR L44 OR L45 OR L46 OR L47
                OR L48 OR L49 OR L50 OR L51 OR L52)
L54           5 SEA ABB=ON  PLU=ON  L43 AND (L44 OR L45 OR L46 OR L47 OR L48
                OR L49 OR L50 OR L51 OR L52)
L55           0 SEA ABB=ON  PLU=ON  L44 AND (L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51 OR L52)
L56           5 SEA ABB=ON  PLU=ON  L45 AND (L46 OR L47 OR L48 OR L49 OR L50
                OR L51 OR L52)
L57           7 SEA ABB=ON  PLU=ON  L46 AND (L47 OR L48 OR L49 OR L50 OR L51
                OR L52)
L58           9 SEA ABB=ON  PLU=ON  L47 AND (L48 OR L49 OR L50 OR L51 OR L52)
L59           5 SEA ABB=ON  PLU=ON  L48 AND (L49 OR L50 OR L51 OR L52)
L60           1 SEA ABB=ON  PLU=ON  L49 AND (L50 OR L51 OR L52)
L61           2 SEA ABB=ON  PLU=ON  L50 AND (L51 OR L52)
L62           4 SEA ABB=ON  PLU=ON  L51 AND L52
L63          18 SEA ABB=ON  PLU=ON  (L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR
                L59 OR L60 OR L61 OR L62)

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 17:14:40 ON 21 JUL 2008
L64          19 SEA ABB=ON  PLU=ON  L63

     FILE 'WPIX' ENTERED AT 17:16:43 ON 21 JUL 2008
L65           9 SEA ABB=ON  PLU=ON  (L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR
                L59 OR L60 OR L61 OR L62)

     FILE 'ZCAPLUS' ENTERED AT 17:17:27 ON 21 JUL 2008
                D STAT QUE L63

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 17:17:44 ON 21 JUL 2008
                D STAT QUE L64

     FILE 'WPIX' ENTERED AT 17:18:07 ON 21 JUL 2008
                D STAT QUE L65

     FILE 'STNGUIDE' ENTERED AT 17:18:18 ON 21 JUL 2008

     FILE 'ZCAPLUS, MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 17:18:25 ON 21
     JUL 2008
L66          19 DUP REM L63 L64 L65 (27 DUPLICATES REMOVED)
                     ANSWERS '1-18' FROM FILE ZCAPLUS
                     ANSWER '19' FROM FILE BIOSIS
                D IBIB ABS L66 1-18
                D IALL L66 19

     FILE 'REGISTRY' ENTERED AT 17:19:29 ON 21 JUL 2008

     FILE 'ZCAPLUS' ENTERED AT 17:19:33 ON 21 JUL 2008
                D STAT QUE L4

     FILE 'BABS' ENTERED AT 17:19:42 ON 21 JUL 2008
                D STAT QUE L8

     FILE 'BEILSTEIN' ENTERED AT 17:20:00 ON 21 JUL 2008
                D STAT QUE L16

     FILE 'WPIX' ENTERED AT 17:20:17 ON 21 JUL 2008
                D STAT QUE L27
```

```
     FILE 'MARPAT' ENTERED AT 17:20:25 ON 21 JUL 2008
                D STAT QUE L29

     FILE 'ZCAPLUS, BABS, WPIX, MARPAT' ENTERED AT 17:20:46 ON 21 JUL 2008
L67           29 DUP REM L4 L8 L27 L29 (5 DUPLICATES REMOVED)
                     ANSWERS '1-6' FROM FILE ZCAPLUS
                     ANSWERS '7-29' FROM FILE MARPAT
                D IBIB ABS HITSTR L67 1-6
                D IBIB ABS QHIT L67 7-29

     FILE 'BEILSTEIN' ENTERED AT 17:24:39 ON 21 JUL 2008
                D STAT QUE L22
                D STAT QUE L16
                D IDE ALLREF L16 1,20,40,50,60


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   20 JUL 2008  HIGHEST RN 1035004-20-6
     DICTIONARY FILE UPDATES:  20 JUL 2008  HIGHEST RN 1035004-20-6

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE ZCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS is
     strictly prohibited.

     FILE COVERS 1907 - 21 Jul 2008  VOL 149 ISS 4
     FILE LAST UPDATED: 20 Jul 2008  (20080720/ED)

     ZCAplus now includes complete International Patent Classification (IPC)
     reclassification data for the second quarter of 2008.

     New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BEILSTEIN
FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
FILE CONTAINS 10.322,808 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```
**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE   *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE          *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                        *
* FOR PRICE INFORMATION SEE HELP COST                                *
**********************************************************************
```

>>> Price change as of January 1st, 2008: Connect Time and Structure Search fees re-introduced. See NEWS and HELP COST <<<

FILE BABS
FILE LAST UPDATED: 14 JUL 2008 <20080714/UP>
FILE COVERS 1980 TO DATE.

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE CAPLUS

FILE COVERS 1907 - 21 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 20 Jul 2008 (20080720/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 18, 2008 (20080718/UP).

FILE WPIX
FILE LAST UPDATED: 15 JUL 2008 <20080715/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200845 <200845/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of March 2008. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC and 20080401/UPIC.
ECLA reclassifications to April and US national classifications to the end of January 2008 have also been loaded. Update dates 20080401/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.p

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Please note that the COPYRIGHT notification has changed <<<

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 149 ISS 2 (20080718/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20080139418 12 JUN 2008
DE 102006057118 05 JUN 2008
EP 1930004 11 JUN 2008
JP 2008127427 05 JUN 2008
WO 2008070241 12 JUN 2008
GB 2443936 21 MAY 2008
FR 2909090 30 MAY 2008
RU 2325390 27 MAY 2008
CA 2568954 27 MAY 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT have increased from 100,000 to 200,000 for both on-line and batch searches. For more information on MARPAT search limits, type HELP SLIMITS at an arrow prompt.

FILE MEDLINE
FILE LAST UPDATED: 19 Jul 2008 (20080719/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE EMBASE
FILE COVERS 1974 TO 21 Jul 2008 (20080721/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 16 July 2008 (20080716/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

=>
Uploading L1.str



chain nodes :
10 11 12 13 14 15 23
ring nodes :
1 2 3 4 5 6 7 8 9 16 17 18 19 20 21
chain bonds :
7-23 10-12 10-11 10-23 13-14 14-15 15-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 16-17 16-21 17-18 18-19 19-20
20-21
exact/norm bonds :
5-7 6-9 7-8 7-23 8-9 10-12 10-11 10-23 13-14 14-15 15-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom
22:CLASS 23:CLASS

Uploading L10.str



chain nodes :
1 2 3 4 5 6 13 16
ring nodes :
7 8 9 10 11 12
chain bonds :
1-3 1-2 1-13 4-5 4-16 5-6 6-10 13-16
ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-3 1-2 1-13 4-5 4-16 5-6 6-10 13-16
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12

G1:O,S,N

G2:O,S

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom
11:Atom 12:Atom 13:CLASS 16:Atom
Generic attributes :
16:
Saturation : Unsaturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic